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While the usage of nanoscale materials for therapeutics and diagnostics is growing rapidly, there 
remain many challenges to understanding the expected controlling parameters (e.g., size, shape 
and chemical properties) that significantly affect the performance of the nanomaterials due to 
complicated in vivo environments. Therefore, a strong interest in the knowledge of the nano–bio-
interactions and how they contribute to tissue accumulation has been developed. To date, 
researchers have relied on monolayer cell cultures and animal models to study such nano–bio-
interactions. However, currently, there is a big gap between the result of the over-simplified in 
vitro cell response and the complex animal models, where many biological reactions and organs 
may interact with the nanomaterials. Novel non-expensive microfluidic systems have recently 
been designed to mimic the tumor environment (including extracellular (ECM) tissue and cancer 
cells).  Moreover, well-defined and low-polydispersity lipid-based nanoparticles (NPs) have been 
synthesized into various morphologies such as nanodiscs, vesicles, ribbons, etc. in Prof. Mu-Ping 
Nieh’s research group, and we will test their potential application in cancer drug delivery.  
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Chapter 1. Background and Literature Review 
 
1.1 Background and Literature Review 
Nanotechnology is an emerging research area in biomedical science and engineering, 
promising to overcome issues such as targeting delivery and efficacy of cellular uptake.[1] The 
term “nanotechnology” was invented by Professor Norio Taniguchi of Tokyo Science University 
in the year 1974 to describe precision manufacturing of small-scale materials (1 to 100 nm) that 
can be used in different applications.[2, 3] In recent years, various nanotechnology platforms have 
gained exceptional attention in the area of medical research, including diagnosis and therapy.[4, 5] 
During the past 40 years, research on the nanoparticles for pharmaceutical and medical 
applications have been conducted to investigate the potential of different nanoparticles (NPs) in 
related applications.[6]  Because of the complexity of the human body, these systems of 
nanoparticles should be studied carefully before they can be available commercially. Abraxane™, 
human serum albumin nanoparticles containing paclitaxel, is the first commercial nanoparticle 
product containing a drug appeared on the market at the beginning of 2005.[7]  
The consideration of nanoscale materials in the field of medicine is proven to have efficient 
and safe applications over the last decades.[5, 8-12] However, nanoparticles cannot be considered 
for a clinical application until some of their critical parameters have been carefully examined such 
as physical properties, drug loading efficiencies, drug release potential, and, most importantly, 
minimum toxicity. [13] Therefore, the requirement of more investigation to understand the role of 
nanoparticles’ characteristics in the interaction with the human tissue at the micro level is essential.   
Nanoparticles are attractive for medical purposes because of their unique properties, such as 
high surface area which is larger than that of other particles, fast absorption of other compounds 
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and excellent encapsulation.[14] NPs have a relatively large surface which can bind and carry other 
compounds such as drugs, probes, and proteins.[15, 16]  In many cases, surface modifications 
promote the functionality of these nanocarriers to achieve the maximum functionality of the 
carrying systems. Researchers have also found that the size, shape and surface chemistry of 
nanocarriers for biological and medical agents can dictate their efficacy.[17, 18]     
Currently different materials are under investigation for drug delivery and more specifically 
for cancer therapy. Polymer-Based nanoparticles have been demonstrated high efficacy in cancer 
targeting.[19] These systems include polymeric drugs, polymer-protein conjugates, polymer-drug 
conjugates, and polymeric micelles.[20] These biocompatible polymers can be either synthesized 
or nature-derived indicating antiviral or antitumor properties.[21, 22] One of the most commonly 
used polymers to enhance the biocompatibility is polyethylene glycol  (PEG) which allows 
nanoparticles to have a longer in vivo circulating time.[23, 24] PEG-drug conjugation is also 
applied to improve drug solubility and specificity of low molecular weight drugs. Lastly, polymeric 
micelles (PMs) composed of amphiphilic polymers are commonly used to entrap poorly water-
soluble drug in the hydrophobic core of the micelles which protect the drug from the aqueous 
environment and stabilize the PMs against recognition in vivo by the reticuloendothelial system 
(RES).[25, 26]  
Anticancer nanoparticles have made a tremendous impact in the treatment of various types 
of cancer, as proved by clinical use.[27] Recently, many review papers have presented different 
examples of numerous liposomal and polymer based drugs systems.[28, 29] PEGylated liposomal 
doxorubicin is one of drug formulations that is used for cancer treatment.[30, 31] The hydrophilic 
doxorubicin can be encapsulated in the water core of liposomes (vesicles). The general size of the 
vesicle is approximately 100 nm in diameter and shielded by a dense layer of polyethylene glycol 
3 
 
 
(PEG).[32] PEG attachment improves the reduction of the renal clearance of drugs and thus 
enhances uptake by cells. As a result, the lipid/drug complex has extended half-life and hence the 
frequency of drug administration is reduced.[31] Although nanoparticles have demonstrated 
enhanced efficacy to detect and treat cancer cells, the number of nanoparticle-based medicines 
approved for clinical use remains low[33] mainly because of the complexity of nanoparticles 
interacting with the human tissue. Hence, careful design of the nanoparticles and detailed analysis 
of the structure-function relationship are urgently needed. For that, researchers have been working 
to overcome any challenges developing smart therapeutics that are more effective and less toxic.   
Lipid- based nanoparticles have the advantage of high biocompatibility and most of the lipids 
have been FDA approved and commercially used for in vivo anticancer drug carriers. Liposomes 
have been extensively reported as an example of lipid-based nanocarriers, which mainly consist of 
phospholipids (major components of biological membranes) and cholesterol.[34] They showed 
enhancement in biomedical applications in the aspects of stabilizing therapeutic compounds, 
enhancing cellular and tissue uptake, and improving in vivo biodistribution of drug 
compounds.[35-37]. The formation of liposomes is based on the physiochemical properties of the 
phospholipid molecules, which have hydrophobic and hydrophilic components, forming 
bilayers.[35-38] The size of liposomes can range from tens to thousands of nanometer.[20] 
Hydrophilic drug molecules can be encapsulated within the fluid enclosed by the vesicular lipid 
bilayers. Such encapsulation protects drugs from early inactivation, degradation, dilution in the 
circulation, while maintains minimal toxicity.[39] Since the 1980s, liposomes have been used in 
clinical applications, providing the efficacy of therapeutics, such as doxorubicin and amphotericin. 
[35, 36, 40] 
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Recently low-polydispersity lipid-based nanodiscs were found spontaneously forming in a 
mixture composed of long- and short- chain phospholipids.[41] These nanodiscs are capable of 
entrapping hydrophobic molecules in the bilayer core and have a robust formation mechanism,[42, 
43] allowing large-quantity nano-manufacturing of the NPs. Most importantly, a transition of 
nanodisc-to-nanovesicle also takes place as the structure of long-chain lipid varies from the low-T 
gel (order) to high-T Lα (liquid disorder) phase. These nanovesicles are also uniform in size (low-
polydispersity) and go through the irreversible formation at low lipid concentration even when the 
temperature reverts to the initial low T, where the long-chain lipid is in the gel phase.[43-45]  Such 
properties allow us to produce different low-polydispersity morphologies from materials of the 
same chemical composition and enable our investigation on the morphological dependence of NPs 
as they interact with the cells while the other physicochemical characteristics remain constant. 
Note that these phospholipids are also biocompatible; thus, suitable for therapeutics or diagnostics 
applications of nanocarriers. However, the efficiency of these nanoparticles served as delivery 
vehicles remain unpredictable because of poor control over the way of interaction between carrier 
systems and the tumor tissue in vivo.[4] To overcome this problem, a better understanding of how 
nanoparticles (based on their size, morphology, and surface modification) interact and distribute 
at the cellular level in the tumor site is required.  
Another important characteristic for effective drug delivery carriers is the local 
accumulation of NPs at the desired locations to enhance the cellular uptake.[5, 46-49] Based on 
several in vitro and in vivo studies, it has been reported that tumor accumulation of particle is 
affected by their size, shape, and surface chemistry.[18, 46] Recent studies indicated that the 
cellular uptake of nanoparticles depends not only on their chemical compositions but also the 
physical parameters such as shape and size [46, 49-53] as well as the cell lines used in the 
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study.[54] For example, under typical physiologically relevant conditions for several cell types, 
polymeric disc-shaped hydrophilic particles with diameters of 325 nm and 220 nm can be 
internalized more efficiently compared to nanorods or smaller-sized nanodiscs (80 nm in 
diameter).[54] However, the effect of the morphology of NPs on cellular uptake can only be 
unambiguously deduced based on the NPs made of the same chemical compounds and 
compositions. 
Furthermore, targeting to molecular markers overexpressed on the surface of diseased cells 
can enhance the specificity and efficacy of delivery and decrease the potential damage to healthy 
tissues.[55] The vasculature in tumor tissues is usually leaky to macromolecules, and the tumor 
lymphatic system is deficient,[38] allowing nanoparticles with diameters < 100 nm to be 
preferentially delivered to the tumor through the enhanced permeation and retention (EPR) effect 
via blood vessels.[56] That is also known as “passive targeting,” where the specificity is only based 
on size. Therefore, it is important to develop a more accurate and active system that could target 
the tumor and enhance intracellular uptake of NPs in the tumor sites. [57] This is called “active 
targeting.” Another approach is to decorate the surface of NPs with molecules or ligands which 
target the overexpressed proteins on the surface of cancer cells. The targeting ligands can be small 
molecules or antibodies. This would presumably further improve the delivery of drugs to the 
targeted site in the human body.[33] The addition of targeting ligands allows the delivery of 
nanoparticles to target specific cells, thereby hoping to reduce the unwanted systemic exposure of 
cytotoxic drug.[57] The potential use of receptor-based actively targeting nanoparticles has drawn 
tremendous interest in their applications for diagnostic and therapeutic delivery.[58-60] Numerous 
targeting ligands have been investigated as biomarkers for targeted drug delivery including 
antibodies, antibody fragments, aptamers, peptides and different receptor ligands (e.g., folic 
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acid).[58-60] 
The fact that folate receptor (FR) expression is high in many human cancers including 
kidney, brain, ovarian, lung, breast and colon cancers prompts the application of folic acid for a 
targeting ligand.[61, 62] FR has two glycosyl phosphatidylinositol-anchored isoforms: alpha 
and beta.[63] The expression of FR-alpha is frequently observed in epithelial cancer cells, 
whereas FR-beta expression is found in leukemia and inflammatory disease.[64] Therefore, FA 
is considered to be an attractive agent for tumor-specific drug delivery. Another important 
feature of FR is its location on the membrane of epithelial cancer cells, which is different from 
the membrane of normal cells.[65] It should be noted that folic acid has a very high binding 
affinity (Kd ∼10-9 M) with FR and can be conjugated to the surface of NPs, enhancing the 
delivery and cellular uptake.[66] Several studies verified that folic-acid-drug conjugates are 
efficient for folate targeting.[62, 67-69] 
The efficacy of nanoscale-sized folate receptor-targeted conjugates called doxorubicin-
polyethylene glycol-folate (DOX-PEG-FOL) aggregates was tested for the treatment of cancer in 
2004 at the Korean Advanced Institute of Science and Technology.[70] The results of this study 
demonstrated a significant reduction in the size of the tumor using folate-targeted doxorubicin 
nano-aggregates compared to non-targeted doxorubicin aggregates or free doxorubicin.[70] In 
another study folate-PEG-chitosan-graft-low polyethyleneimine (FPCP) has been reported as a 
cancer cell-targeting gene carrier because of specific ligand-receptor interactions between folate 
molecules and the folate receptor.[71] More recently, folate receptor directed mercaptosuccinic 
acid-coated gold nanoparticles (GM) for detecting and imaging oral cancer were tested in 
vitro using KB cells and animal skin cells (NIH3T3).[72] The results showed that the folic acid 
linked GM could specifically target oral cancer cells and emit intense fluorescence for imaging, 
revealing more efficient intracellular uptake into KB cells compared to the other cell line used in 
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the study.[72] A novel lipid-polymer hybrid drug carrier comprised of folate (FA) modified lipid 
shell and polymer-core nanoparticles (FLPNPs) loaded with paclitaxel were developed for breast 
cancer treatment.[73] The outcomes of this study showed improvement of the cellular specific 
uptake and tumor size reduction with a minimum cytotoxicity.[73]  These results suggested that 
folate-targeted paclitaxel nano-aggregates could be a useful delivery system for folate-receptor-
positive cancer cells. Therefore, designing an applicable NPs, whose surface is coated with folate, 
as a delivery system is important to guide carriers to cancer cells. Afterward, the drug carriers are 
then internalized via receptor-mediated endocytosis.  
The study of nanoparticles’ efficiency is usually achieved through in vitro experiments of 
animal or human cell cultures or in vivo animal models. However, the data of the interaction 
between the nano-carriers and the cell gained from in vitro cell monolayer experiments is mostly 
limited to characterization of the binding affinity, uptake, cellular responses and toxicity of the 
nanoparticles.[46, 54, 74, 75] The absence of a three-diminution (3D) tissue structure makes these 
findings inaccurate to predict the in vivo results. Many pieces of evidence suggest that the 3D 
tumor models replicate more accurately the actual microenvironment of the tumor than the 2D cell 
model since they lose their phenotypes as are cultured in 2D environments; therefore, the behavior 
of 3D tumor model would reflect more closely the in vivo responses.[76-79] In vivo animal models 
have been applied to assessing general pharmacokinetics[80-82], and the effects of size, shape, 
surface modification and the composition of delivery carriers on their efficacy.  However, it has 
been hard to visualize target tissues at the cellular level in animal models because of the low 
resolution of whole-animal imaging techniques.[83] Thus, it will be more efficient if a replication 
of the in vitro 3D animal model with accessible and well-controlled microenvironment is 
established to study the behavior of nanoparticles.  
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Hence, an easily prepared 3D cell culture model would be an alternative to mimic animal 
models. Multicellular spheroid (MCS) is one of the most well-known models used in this matter; 
it was first demonstrated by Holtfreter [84] and Moscona [85] using suspended cells to form the 
spheroid through a self-assembly process. Most MCS are similar to real human tissues in many 
aspects compared to monolayer cell cultures.[86] Many challenges prevented using spheroid tissue 
models for studying drug delivery in the past.[87] The formation of spheroids in uniform size and 
shape is one of the most common obstacles that prevented the use of spheroids in biomedical 
studies.[88] Another challenge is the difficulty of forming spheroids with an insufficient number 
of cells or using different types of cells to form tissue-like spheroids.[89] Nevertheless, the 
techniques allows the production of uniform, multi-cell-type spheroids to investigate drugs and 
drug delivery systems in vitro.[86] The comparable outcome  of spheroids to that of the in vivo 
tissues validates the feasibility of using them to study the drug diffusion to organs.[86] Cancerous 
cells can also grow into multicellular spheroids, providing a model for testing drugs and their 
carriers.[90]  
In the early 80s, the microfluidic technology started to emerge into biomedical studies, 
and more effort was required to improve the usage of this technique. Nowadays, microfluidic 
approaches are used in various research fields such as molecular and cell biology.[91] The 
advantages of the microfluidic device to grow in vitro tumor include better control of the cellular 
microenvironment and analyzing cellular interaction at the micro level.[92] Using 
microstructures to guide multicellular self-assembly is an emerging and powerful technique for 
generating MCS with well-controlled size and morphology.[93-97] Several chip-based MCS 
culture systems have been recently developed for comprehensive drug screening.[98] 
Microwells and microchannels were designed in these chips which trap thousands of MCS into 
arrays and then testing chemicals were delivered through the channels.[99] Cellular behavior 
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such as viability, chemical signaling, and responses can be extensively studied in real time on 
the microchip by a variety of methods.[100, 101] In 2005, a drug screening microchip was 
fabricated to examine the effect of antiallergic agents by detecting the released histamine from 
suspended cells.[102] The microchips have been proved to be capable of antiallergic drug 
screening by measuring the inhibition of histamine released from cells.[102] Recently, concave 
microwells with different diameters were used to form 3D tumor models and to test the effect 
of drug loaded nanoparticles. After 96 hours, scanning electron microscopy was used to monitor 
the tumor, and the results revealed a reduction in the size of the smallest tumor whereas the 
larger tumor did not show any changes.[103] 
Another application of MCS-on chip is detecting the optimal conditions for stem cell 
differentiation to improve tissue engineering.[101] In 2006, a study by a group from WiCell 
Research Institute of a 3D microwell-based cell culture was used to keep human embryonic stem 
cells (hESC) from differentiating for weeks.[104] The growth of cells aggregates was controlled 
by different patterns of extracellular matrix (ECM) which revealed in maintaining the viability 
of hESCs for 2–3 weeks.[104] Moreover, microfluidic devices or microchips have been used 
extensively in the past few years to replicate human organs. Organ-on-a-chip is a merge tool to 
provide more valuable features than the animal models, which are expensive and require longer 
preparation time while sometimes fail to predict human responses.[105] A 3D microchip was 
fabricated to create a specific disease model of breast cancer that replicate the relations between 
metastatic breast cancer cells and their migration via vascular endothelium and bone tissue.[106] 
The model employed human umbilical vein endothelial cells in a 3D collagen gel microfluidic 
channel that contained bone cells. Cancer metastasis was then examined using high-resolution 
real-time microscopy to measure the migration of metastatic breast cancer cells in the vascular 
channel and their fate into the bone matrix.[106] The concept of the organ-on-a-chip can be used 
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as a critical measurement of therapeutic drugs to speed up the process of clinical trials. The 
potential of this approach was investigated in a recent study in which a 3D assay of epithelial-
mesenchymal transition during cancer progression was developed. Lung cancer spheroids were 
cultured in a 3D matrix gel with endothelial coating microchannel to study the effect of 12 drugs 
on the behavior of cancer cells. The results were analyzed by direct visualization of the cancer 
spheroids. Interestingly, the results were not consistent with results from 2D culture.[107]  
Another phenomenon observed among certain cancer patients is  multidrug resistance where 
cancer cells develop resistance to chemotherapy drugs. This presents a major barrier to the 
treatment of different types of cancer.[108] For that, a better understanding of the interaction 
between the drugs or their carriers with the tumor is essential to develop high impact carriers that 
penetrate through the entire tumor cells. Several 3D in vitro studies have been performed to 
evaluate the diffusion of the chemotherapeutic drug in the human tissue;[109-112] however, the 
role of pharmaceutical carriers design in tumor accumulation is not well addressed. There have 
been only a few studies applying microfluidic devices to evaluate the relationship between 
nanoparticles physiochemical properties and their penetration into the tumor.[111, 113-115] A 
group from University of Washington developed a 3D microchamber to study the penetration of 
fluorescently labeled nanoparticles prepared in three different sizes (40, 100, 500 nm) and monitor 
their transportation in cell–gel soft tissue cultures. The results of this study demonstrated the 
impact of the size of the nanoparticles on their penetration inside tumor tissue.[116] More recently 
another study was conducted to evaluate the effect particle shape, size and density on their 
transportation within blood vessels in microchannel model. In this study, different types of 
nanoparticles were prepared in various sizes and densities were tested in a fibronectin-coated 
microfluidic channel. The results showed completely different migration rates based on the 
physiochemical properties of the nanostructures.[117]  These researchers were mainly focus on the 
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effect of the size, instead of the morphology or surface modification (with targeting molecules), of 
the NPs on their distribution in the tumor.[115, 116] These studies suggested the microfluidics can 
serve as an approach for the rapid and profitable pre-screening of nano-carriers, providing 
sufficient data to model the transport process before full animal studies.[118] Therefore, our 
knowledge of the effect of both shape and surface targeting molecules of the NPs on penetration 
and tumor accumulation can be further advanced.  
1.1 Dissertation Objectives:   
This dissertation focuses on the fundamental knowledge of the effect of the NP shape on the 
cancer cellular uptake (adherent and suspension cells) and the endocytic pathways. Furthermore, 
this work investigates the efficacy of the NPs in the presence and absence of the folate group, 
which targets the receptor on the surface of cancer cells. Finally, a three-dimensional (3D) tumor 
model using a microfluidic device is constructed to allow real-time imaging and analysis of the 
penetration of the NPs under a physiological condition.    
The outcome of the abovementioned research serves the functions to reveal the 
morphological dependence of cellular uptake (including the internalization mechanism). 
Moreover, the targeting effect of folate modification on the cellular uptake will be investigated 
using the 3-D tumor model to fill the gap between the over-simplified 2D cell model and 
complicated 3D in vivo tumor model to investigate the trafficking of the NPs in the tumor tissue. 
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Chapter 2. The Morphology of Self-Assembled Lipid-Based Nanoparticles 
Affects Their Uptake by Cancer Cells 
 
Abstract 
The morphology of nanoparticles (NPs) has been presumed to play a major role in cellular uptake 
and in vivo stability. This report experimentally demonstrates such dependence by using two types 
of uniform-sized self-assembled lipid-based NPs, namely nanodiscs and nanovesicles, composed 
of identical lipid composition. The morphology is characterized by small angle neutron scattering, 
dynamic light scattering, and transmission electron microscopy. Both NPs have similar bio-
stability in serum and cellular cytotoxicity. However, cellular uptake of the nanodiscs at 37°C is 
consistently and significantly higher than that of the vesicles according to the uptake results of 
several human cancer cell lines, i.e., CCRF-CEM, KB, and OVCAR-8, indicating a strong 
morphological dependence of cellular internalization. Further studies on such morphological 
dependence using CCRF-CEM reveals that vesicles only use Clathrin- and caveolae-mediated 
endocytic pathways, while nanodiscs also take the additional routes of macropinocytosis and 
microtubule-mediated endocytosis. 
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2.1 Introduction  
Nanoparticles (NPs) have been extensively investigated for biomedical applications as 
carriers for theranostics delivery[5, 75, 119] and molecular imaging.[9, 120] In addition to passive 
targeting delivery of nanoparticles to the desired locations via enhanced permeability and retention 
(EPR) effect, enhancing the cellular uptake is also an important parameter to achieve the high 
efficacy of the drug delivery.[5, 46-49]  Studies suggest that the size and shape of a pharmaceutical 
carrier can affect its circulation in the blood, distribution in organs, intracellular transport, and the 
in vivo fate.[121] For example, trastuzumab-coated polystyrene microrods showed 15-fold 
enhancement of the uptake by SK-BR-3 cells compared to that of the spherical particles which 
were only five-fold higher than that of the uncoated particles.[122] In another study, the cellular 
uptake of cylindrical and spherical NPs produced by self-assembly of poly (acrylic acid) and 
polystyrene diblock copolymers was compared. The results revealed that the uptake of spherical 
NPs by Chinese Hamster Ovary cells was higher than that of the cylinder.[123] These studies 
suggest that the influence of the NPs shape on the enhancement of cellular uptake cannot be 
universal to a specific morphology; however, other parameters such as cell types, and materials 
used for NPs are also important.  
Despite these studies, only a few materials have been examined to correlate the morphology of 
particles with the cellular interactions, and moreover, the length scale of interest was mostly in the 
size range of microns, instead of nanometers.[124-127] However, it is known that EPR effect 
works best for NPs with a size less than 100 nm.  It has been reported that the diffusion of Au NPs 
across the tumor extracellular matrix is strongly sized dependent; particles in size range of ~ 20 
nm or smaller showed superior penetration compared to larger Au NPs.[128] Also, an in vivo study 
on gold NPs of a size < 10 nm indicated better penetration in the breast cancer tumor spheroids 
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than the larger NPs did.[129] It has also been reported that, while larger polymeric micelles (~ 100 
nm) were able to diffuse through highly permeable tumors, only NPs in 30 nm size were able to 
penetrate poorly permeable tumors.[130]  
It should be noted that the cellular uptake of NPs depends on their chemical compositions in 
addition to their physical parameters (e.g., shape and size).[46, 48-53] Most of the studies on 
morphological dependence focused on metals or polymers. The correlation between cellular 
internalization and the nano-scaled morphology of biologically relevant materials (e.g., lipids, 
biosurfactants and proteins), though necessary, remains largely unexplored. The main challenge is 
the production of NPs with uniform, distinct nanoscopic structures but composed of the same 
chemical composition. Recently, low-polydispersity lipid-based nanodiscs, also known as bicelles, 
were found spontaneously forming in a mixture consisting of long- and short- chain lipids.[131] 
These bicellar nanodiscs can self-assemble robustly and are capable of entrapping hydrophobic 
molecules.[42, 43] A nanodisc-to-nanovesicle structural transition can also take place as the long-
chain lipid melts from the low-temperature gel (order) to the high-temperature Lα (liquid disorder) 
phase. Both nanodiscs and nanovesicles are uniform in dimensions. At low lipid concentrations, 
the nanovesicles irreversibly form and would not revert to nanodiscs even when the long-chain 
lipid becomes gel phase as the temperature drops below its melting point.[43-45] These properties 
allow us to produce NPs of different morphologies, and low-polydispersity from the identical 
chemical compositions[43], thus enabling a non-bias investigation on the interaction between the 
NPs and the cells upon the variation of NP morphology while other physicochemical 
characteristics were kept invariant.  
The global (average) structure and polydispersity of the NPs in this study were characterized using 
small angle neutron scattering (SANS) and dynamic light scattering (DLS), further confirmed by 
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the transmission electron microscopy (TEM) data. The SANS patterns of the bicellar nanodiscs 
and nanovesicles are distinct from each other and can be best fitted by the discoidal and core-shell 
oblate models, respectively. DLS can provide the polydispersity and the hydrodynamic radii, RH 
of the NPs based on the assumption of Stokes-Einstein relationship for spheres.  
In this report, we will present the dependence of cellular uptake and internalization mechanisms 
on NP morphology using fluorescence activated cell sorting (FACS) and fluorescence confocal 
optical microscopy (FCOM). Several significant findings are described as follow: First, two 
definite and uniform lipid-based NPs entrapping hydrophobic dyes of the identical chemical 
composition can be produced in the forms of nanodiscs and nanovesicles, and are found stable in 
serum.  Second, the cellular uptake of nanodiscs is significantly higher than that of the similar-
sized vesicles under the identical physiological conditions. Third, the nanodiscs utilize two 
additional cellular internalization mechanisms, i.e., macropinocytosis and microtubule-mediated 
transport in addition to the common clathrin- and caveolae- mediated pathways, which appeared 
to be the only routes taken by the nanovesicles. Finally, the enhanced endocytosis in the case of 
bicellar nanodiscs is observed consistently in three different cell lines (i.e., CCRF-CEM, KB, and 
OVCAR-8) of our study.  
2.2 Materials  
Dipalmitoyl phosphatidylcholine (di-16:0, DPPC), dipalmitoyl phosphatidylglycerol (DPPG), 
dihexanoyl phosphatidylcholine (di-6:0, DHPC), polyethylene glycol (PEG2000)-conjugated 
distearoyl phosphoethanolamine (DSPE-PEG2000), and 1-palmitoyl-2-{12-[(7-nitro-2-1,3-
benzoxadiazol-4-yl) amino] dodecanoyl (NBD-PC) were purchased from Avanti Polar Lipids 
(Alabaster, AL, USA) and used without further purification. Nile Red (NR), phosphate buffered 
saline (PBS) powder and all pharmacological inhibitors were purchased from Sigma-Aldrich (St. 
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Louis, MO). Sepharose CL-6B was purchased from GE Healthcare (Pittsburgh, PA, USA). Cell 
Titer Blue kit was purchased from Promega (Madison, WI, USA). Dulbecco’s Modified Eagle 
Medium (DMEM), phenol-free RPMI-1640 medium, Dulbecco's Phosphate-Buffered Saline 
(DPBS), fetal bovine serum (FBS), HEPES-buffered saline (HBS), and Hoechst 33342 were 
purchased from Life Technologies (Grand Island, NY, USA). 
2.2.1 Cells 
Human lymphoma CCRF-CEM cell line was cultured in phenol-free RPMI-1640 media 
supplemented with 10% FBS and 1% penicillin at 37˚C in 5%CO2 and 95% humidified air.  
Human cervix carcinoma KB cells were grown continuously as monolayers using DMEM media 
containing 10% FBS at 37 °C in a 5% CO2 and 95% air humidified atmosphere. 
Human ovarian carcinoma OVCAR-8 were cultured as a monolayer in phenol-free RPMI-1640 
media supplemented with 10% FBS and 1% penicillin at 37˚C in 5%CO2 and 95% humidified air. 
2.3 Methods 
2.3.1 Preparation and Characterization of Nanoparticles  
Dipalmitoyl phosphatidylcholine (di-16:0, DPPC), dipalmitoyl phosphatidylglycerol (DPPG), 
dihexanoyl phosphatidylcholine (di-6:0, DHPC), polyethylene glycol (PEG2000)-conjugated 
distearoyl phosphoethanolamine (DSPE-PEG2000), and 1-palmitoyl-2-{12-[(7-nitro-2-1, 3-
benzoxadiazol-4-yl) amino] dodecanoyl (NBD-PC) or Nile Red (NR) were used for NPs 
preparation. Details on the characterization of lipid NPs are given in (Supplementary Materials). 
The molar composition of the mixture follows DPPC/DHPC/DPPG/DSPE-PEG2000/NR = 
66.25/25/3.75/5/0.002. If NBD-PC is included, it has the same composition as NR. All components 
of the required weights were first homogenized in chloroform. After the removal of solvent in a 
vacuum oven, the dried samples were then re-dispersed in filtered D.I. water (or D2O if the samples 
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were for SANS measurements) to make stock suspensions with a total lipid weight concentration, 
Clp of 10 wt%. After successive vortex and temperature cycling between 25 and 70°C, the samples 
were completely homogenized. The 10 wt% stock dispersions were then progressively diluted at 
room temperature to Clp = 1.0, 0.5 and 0.25 mg/ml with either water (or D2O for SANS), 140 mM 
NaCl aqueous solution or phosphate buffered saline (PBS) solution, depending on the usages (i.e., 
DLS, SANS, stability or cellular uptake studies). 
2.3.2 Nanoparticles Size Analysis and Characterization (Thanks to Ying Lue) 
2.3.2.1 Dynamic Light Scattering 
Size and population distribution of nanodiscs and vesicles were determined by DLS 
measurements using a Malvern instrument (NANO ZS, Malvern Instruments, CA, USA). For a 
typical sizing experiment 10 µl of NPs was diluted in 390 ml, HBS were placed into a Zeta-sizer 
cuvette. Each run consisted of 3 measurements of 12 to 20 acquisitions.  
2.3.2.2 Small Angle Neutron Scattering 
SANS data were collected using the EQ-SANS instrument at the Spallation Neutron Source at 
Oak Ridge National Laboratory. The sample-to-detector distance was set to 4.0 m. A 25 mm source 
aperture and a 10 mm sample aperture were used to collimate the incident beam. The instrument 
was operated in the 30 Hz “frame-skipping” mode with a minimum wavelength setting of 2.5 Å, 
providing a second wavelength band starting at 9.4 Å resulting in a combined q-range (q = 
4𝜋
𝜆
𝑠𝑖𝑛
𝜃
2
, 
where θ is the scattering angle and λ is the neutron wavelength) covering 0.007 ~ 0.40 Å−1. The 
data fitting was performed in the q-range from 0.007 to 0.25 Å−1, since incoherent scattering 
dominates the higher q range. Data correction followed standard procedures implemented in 
MantidPlot (http://www.mantidproject.org/) to correct for sample transmission, detector 
sensitivity, and dark background before circularly averaging the 2D data around the beam center 
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to produce I(q) versus q. The data from the two wavelength bands were also merged into a single 
profile using MantidPlot. 
2.3.2.3 Transmission Electron Microscopy 
The negatively staining TEM micrograph was obtained by an FEI Tecnai T12 transmission 
electron microscope.  The samples were prepared in the following steps. A drop of 5 μl solutions 
in a concentration of 0.01 mg/ml was first placed on a 400 mesh copper grid coated with 
Formvar/carbon film (Electron Microscopy Sciences, PA, USA). The excessive solution was then 
blotted with Whatman filter paper. Then, the sample was negatively stained with five μl of 10 
mg/ml Uranyl acetate (SPI Supplies, PA, USA) and the excessive staining solution was again 
removed with the filter paper. Afterward, the grid was dried at room temperature. Electron 
micrographs were taken at an accelerating voltage of 80 kV. 
2.3.2.4 Polydisperse radius disc (PRD) model 
In regards to nanodiscs, the scattering pattern can be described by a polydisperse radius disc 
(PRD) model, where the thickness, t (= 2H) of the discs is assumed constant (only a function of 
temperature) and the radii, r of the discs follow the Schulz distribution (as shown in Scheme 2.1). 
As a result, the size averaged form factor, PPRD (q) of the PRD model is mathematically described 
by the following equations: 

2/
0
2
0
sin),()(
1
)(

 dqAdrrf
V
qP PRD
x
PRD
PRD  ,   (1) 
APRD(q)= 2VPRD(rlip -rD2O ) j0(qH cosa)
J1(qrsina)
(qrsina)
, 
Where is an angle between bilayer normal and scattering vector, q. VPRD and APRD (q) represent 
the volume of the individual disc and the scattering amplitude of the nanodisc, respectively. The 
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functions J1(x) and Jo(x) are the Bessel function of the first kind and
𝑠𝑖𝑛𝑥
𝑥
, respectively. Eq. (1) 
includes the average over all possible orientations and various size of discs according to Schulz 
distribution, f(r) as expressed below.  
 
Scheme 2.1. A sketch of the disc with a thickness of t (=2H) and a radius of r. 
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Where p is the polydispersity of the size defined by R/<R> with R and <R> being the standard 
deviation and average of r. 
2.3.2.5 Oblate Single-Shell (OSS) Model 
The oblate single-shell (OSS) model (with two identical long-axes and one short-axis) was used 
to fit the SANS data as shown in Scheme 2.2. This model contains four independent parameters to 
describe the dimension of the particle, namely the major (rbi) and minor (rai) axes of the core and 
the major (rbo) and minor (rao) axes of the shell.  
The form factor and scattering amplitude of OSS model, i.e., POSS (q) and AOSS (q) can be expressed 
as follow 
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Where core and total volumes (Vi and Vo) can be mathematically derived as 
aibii rrV
2)3/4(   and, aibio rrV
2)3/4(   
2/12222 ])1([  aibii rrqu  , 
2/12222 ])1([  aoboo rrqu    and  
, b = cosa . 
                          
It should be noted that the OSS model assumes monodisperse particles and the peak smearing in 
the SANS patterns is mainly due to the different lengths and shell thicknesses along the long- and 
short- axes.  
 
Scheme 2.2. A sketch of OSS model with the inner minor radius (rai) and major radius (rbj), and an 
outer minor radius (rao) and an outer major radius (rbo).    
2.3.3 Nanoparticles Stability Assay (Thanks to Dr. Anu & her group)  
To study the stability of the nanoparticles in the presence of serum, NPs of 1 mg/ml were either 
j1(x)= (sin x- xcosx) / x
2
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labeled with NR or NBD-PC (a green dye with lipid tails). NPs (12 µmole Pi/ml) were incubated 
with either HEPES-buffered saline (HBS) or fetal bovine serum (FBS) at a volume ratio of 1:1 
(NP solution: buffer) at 37°C for 2 hours. Samples were then fractionated using a size exclusion 
gel chromatography column (Sepharose CL-6B, 1x40 cm, 40 ml bed volume) pre-equilibrated with 
HBS. Eluted NPs (and/or any released dye) were collected as 1 ml fractions (total 40 fractions) to 
analyze fluorescence and the lipid content following the protocol described in previous 
articles.[132, 133] Fluorescence was measured using a fluorescent microplate reader (SpectraMax 
M2, Molecular Devices, Sunnyvale CA, USA). Filter settings (Ex/Em) of 450/530 nm and 530/605 
nm were used for NBD-PC and NR, respectively. 100% fluorescence was obtained after addition 
of TX-100 (0.02%, final concentration). The recovery of lipids in the fractions was determined by 
measuring inorganic phosphorus (Pi).[132]  
The time-dependent changes in fluorescence of NPs were measured at 37°C. The initial 10 mg/ml 
NPs (nanodiscs or vesicles) in either water or NaCl solution (140 mM) were further diluted with 
either FBS or HBS at 1:1 ratio (v/v). Diluted samples were placed in triplicate in a 96-well plate 
(0.2 ml per well). Fluorescence was measured at zero time, 2 hours and after addition of TX-100 
(0.05% final concentration w/v) using the same filter setting as the previous experiment.   
2.3.4 Cytotoxicity Assay 
CCRF-CEM, KB, and OVCAR-8 cells were used for in vitro cytotoxicity analysis of the self-
assembled lipid nanocarriers using an MTS assay. 104 cells/well were plated overnight in a 96 well 
plate. The NPs were diluted in the media to a final concentration ranging from 0.2 to 1.00 mg/ml 
in the final volume of 50 µl and incubated with cells in triplicate. The following controls were 
used: positive control = NPs + cells + MTS, blank = untreated cells + MTS, and negative control 
= medium + MTS. After incubation with NPs at 37°C for 48 hours, assays were performed by 
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adding the MTS reagent solution to culture wells and incubation continued for 4 hours. The 
absorbance (at 490 nm) was then recorded using a microplate reader. To calculate the percentage 
of cells density, the following formula was used: Cell density= optical density (OD) sample - OD 
blank, then the average of the triplicate sample ODs was calculated. The sample OD from untreated 
cells (blank) was set to 100%, then the percentage of cell density for treated cells was calculated 
by the following ratio: (OD untreated sample (100)/OD sample) *100.  
2.3.5 Cellular Uptake Visualization and Quantification 
FACS was performed on CCRF-CEM, KB, and OVCAR-8 cells after incubation with NPs to 
study cellular uptake and energy-dependent endocytosis. Cells were seeded in a 24 well tissue 
culture plate 24 hours before the tests. Cells were then incubated with NPs in lipid concentration 
of 1.00 mg/ml at 4 and 37°C for 2 hours. For adhering cells, e.g., KB and OVCAR-8 cells were 
first trypsinized and collected, while CCRF-CEM, a suspension cell, was collected directly. All 
cells were then washed and re-suspended using Dulbecco's Phosphate-Buffered Saline (DPBS). 
FACS experiment was conducted using a BD Biosciences FACSCalibur flow cytometer. All 
experiments were performed in triplicates. Emitted light results from NR-labeled nanoparticles 
was detected by the FL-2 detector. To calculate the background fluorescence of unlabeled cells, 
cells without any addition of nanoparticles were carried along as a negative control in every 
measurement. For whole-cell analysis, 104 cells were counted. Data analysis was performed with 
BD CellQuest Pro (BD Biosciences, Heidelberg, Germany).  
The visualization of the NPs uptake by cells was conducted using a Nikon A1R confocal 
microscopy using a 60 x oil immersion lens. Image acquisition and analysis were performed using 
Nikon Elements Ar software. The procedure followed the same incubation conditions for the FACS 
quantification. Before imaging Hoechst 33342 was applied to stain the nuclei.   The intensity of 
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the laser beam and the photodetector sensitivity were kept constant to compare the relative 
fluorescence intensities between experiments.  
2.3.6 Mechanisms of Cellular Uptake 
The relative level of nanoparticle uptake was assessed via FACS. CCRF-CEM cells were 
incubated with endocytosis inhibitors for 30 minutes according to the concentrations of the 
inhibitors listed in (Table 2.1).  
NR-labeled NPs in the concentration of 1.00 mg/ml was then added, and the incubation continued 
for 1.5 hours. After that, cells were washed and resuspended in DPBS. Measurements on the cells 
treated by NPs in the absence of inhibitors were taken as the positive controls and compared with 
those of cells incubated with specific inhibitors and NPs. Concentrations of inhibitors were 
obtained based on 90% cell viability test of each inhibitor after 2 hours of incubation. 
Table 2.1.List of pharmaceutical inhibitors: The concentration of each pharmaceutical inhibitor 
used to determine the internalization mechanism of nanodiscs and nanovesicles. 
2.4 Results and discussion 
2.4.1 Nanoparticles characterization 
The structures and polydispersity of the NPs were characterized by SANS, DLS, and TEM and 
are consistent with the previous report where nanodiscs self-assembled in a homogenized mixture 
of DPPC/DHPC/DPPG/DSPE-PEG2000 in PBS at room temperature.[45, 134]  The nanodiscs 
were proven to be stable if kept at temperatures lower than the melting transition temperature of 
Inhibitors Inhibited mechanism Concentration  
Chlorpromazine Clathrin 140 µM 
Filipin III Caveolae 7.6 mM 
Cytochalasin D Macropinocytosis 10 μM 
Amiloride Macropinocytosis 800 μM 
Wortmannin Macropinocytosis 10 μM 
Nocodazole Microtubules 35 μM 
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DPPC (i.e., 41°C). They underwent a disk-to-vesicle transformation, which is irreversible in the 
sample at low lipid concentrations (≤ 1 mg/ml), i.e., the vesicular structure retained after being 
cooled down to the room temperature.[134] The hydrophobic core of the lipid bilayer can entrap 
hydrophobic or amphiphilic molecules, e.g., NR and NBD-PC in the bilayer. The DLS data (Figure 
2.1 A) showed well-defined hydrodynamic diameters (DH) of the two chemically identical samples 
(one not being heated and the other after being heated at 50°C for overnight) at 25°C. The DH 
values obtained in unheated, and post-heated samples are 21 and 34 nm, respectively, representing 
nanodiscs and vesicles independent of NR or NBD-PC content. Since DLS did not elucidate 
detailed structural information, SANS measurements were also performed to investigate the 
detailed structures of the NPs. (Figure 2.1 B) Shows the SANS data of a 1.0 mg/ml 
DPPC/DHPC/DPPG/DSPE-PEG2000 unheated and the same post-heated samples, respectively. 
Distinct SANS patterns are observed for these two samples, indicative of different structures. The 
SANS curve of unheated sample shows a low-q asymptotic plateau (q being the scattering vector 
defined as 
4𝜋
𝜆
sin
𝜃
2
, where λ and θ are the wavelength of the neutron and the scattering angle, 
respectively) followed by a monotonic decay. A polydisperse discoidal model could best fit the 
data with an average diameter and bilayer thickness of 21.0 and 5.4 nm, respectively – consistent 
with the characteristic of DPPC bilayer structure. The fact that the negatively-stained TEM images 
reveal the plane and edge of discs further confirm the disk-like structure described by the SANS 
model (Figure 2.1C).  
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Figure 2-1.Structural characterization of the nanoparticles: (A) The distributions of hydrodynamic 
diameter, DH of NPs prepared in PBS by DLS. Three measurements at 25°C were taken on each 
sample, and the data were averaged and plotted as intensity-weighed distributions.  (B) SANS data 
of the nanodiscs (purple triangles) at 37°C and the oblate vesicles after annealed at 50°C (red 
squares) with a lipid concentration of 1.0 mg/ml in PBS and their best fits (black curves) using the 
discoidal model and oblate vesicular models, respectively. (C) The negatively staining TEM 
micrographs of nanodiscs at different magnifications. The white and red arrows represent the plane 
and edge of the nanodiscs, respectively. 
The SANS pattern of the same post-heated sample transforms into a curve with several weak 
(A) 
(B) (C) 
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oscillations originated from the high contrast between the vesicular shell and interior/exterior 
solution as well as the low polydispersity of the vesicular radius. It has been previously established 
that the SANS pattern is a unique scattering feature of core-shell vesicular structure in 
literature.[43-45, 131, 135] The SANS data was best fit by an oblate vesicular model with the outer 
long- and short- axes of (34.2 ± 0.5) and (12.0 ± 0.3) nm, respectively. Neither aforementioned 
discoidal model nor other single-morphology, e.g., cylindrical, spherical and vesicular models 
provides reasonable fits with sensible physical parameters. TEM was not applied to examine the 
structure because vesicles do not survive at high vacuum and a cryogenic stage is not available at 
the facility. Based on the same transition and morphology which were observed and reported 
previously, the oblate vesicles are identified with high certainty.[45, 134] The interpretation of 
SANS results is also supported by the hydrodynamic diameters obtained from the DLS 
measurements (Figure 2.1 A).  
It should be noted that both NPs (nanodiscs and vesicles) are made of biologically relevant 
components which have the identical compositions. Moreover, their sizes are similar (< 50 nm), 
and each has a low polydispersity. Therefore, this system enables us to study the shape-dependent 
of NPs on cellular internalization.  
2.4.2 Stability of NPs in Serum  
Before the in vitro cell study, the stability of the NPs must be examined to confirm that most the 
NPs will not alter their morphology, and the entrapped dye (NR or NBD-PC) does not dissociate 
from the NPs. It has been well known that PEG-conjugation (PEGylation) on the surface of NPs 
can effectively reduce the uptake by the reticuloendothelial system (RES) and the non-specific 
interactions between the NPs and the plasma proteins, thus increasing the circulation half-life of 
the NPs.[136, 137] Therefore, DSPE-PEG2000 was also incorporated with the lipid NPs to 
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suppress the lipid/plasma protein interactions in this study. Moreover, it has been reported that the 
bicelle-type nanodiscs tend to coalesce with each other after dilution.[45, 138, 139] The addition 
of DSPE-PEG2000 can effectively inhibit the disc coalescence due to the steric effect of PEG. To 
examine the stability of these lipid NPs and their interactions with serum, NP solutions containing 
FBS was investigated. The NR-containing NPs (either nanodiscs or vesicles) were incubated at 
37°C with either FBS or HBS, and the release of the fluorophore was measured at a given period 
as shown in (Figures 2.2 A, and B). Two high-concentration NP solutions (100 mg/ml) were first 
prepared in either water or 140 mM NaCl saline, respectively, as stock solutions. Afterward, the 
stock solutions were diluted using either FBS or HBS solution to form a solution with lipid 
concentration of 1 mg/ml.    
The retention of NR or NBD-PC from the nanodiscs was monitored based on fluorescence 
intensity initially (t = 0) and after 2 hours of incubation. Fluorescence measurements were also 
conducted on the samples with the addition of Triton-X100 (TX-100), a detergent commonly used 
to destabilize vesicles. The nearly invariant fluorescence in (Figure 2.2 A) indicated that the 
entrapped NR was most likely intact under all conditions. To further confirm the stability of 
nanodiscs in FBS and HBS, a time-resolved fluorescence experiment was conducted over 24 hours, 
and the results are shown in (Figure 2.3). The same type of experiment was also carried out on the 
nanodiscs and vesicles incorporated with a trace amount of NBD-PC, which is well integrated with 
PC lipids and thus can be considered as part of the bilayer. The fluorescence of both NBD-labeled 
nanodiscs and vesicles (Figure 2.2 A) also shows no noticeable differences in the presence or the 
absence of FBS as well as after the addition of TX-100. Thus, we can conclude that both nanodiscs 
and nanovesicles can entrap hydrophobic or amphiphilic molecules with high stability.  
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Figure 2-2. NPs stability in saline and serum: The fluorescence of NPs before and after being 
incubated in the presence (blue bars) and absence (green bars) of FBS at 37˚C for 2 hours and then 
treated with TX-100. The standard deviations of three measurements within a single experiment 
are used as the error bars. The results of (A) NR-containing nanodiscs and NBD-labeled nanodiscs 
and vesicles in the stock solutions which initially prepared in either water or 140 mM NaCl saline. 
(B) Fractionation and elution profiles of NP-containing nanodiscs after being incubated in the 
absence (left, HBS) and presence (right) of FBS for 2 hours at 37˚C. The nanodiscs in HBS were 
eluted from fractions 16 to 25 (dotted red line). FBS also yielded fluorescence signal and was 
eluted from fractions10 to 13 (solid blue line). The nanodiscs in FBS had a wider distribution and 
were eluted from fractions 12 to 25 (red dotted line). 
 
(B) 
(A) 
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Although neither NR nor NBD-PC fluorescence was significantly affected after incubation with 
FBS, the possible change in the morphology of NPs cannot be ruled out. In the case of lipid NPs, 
the morphology normally correlates with the size of the NPs. Therefore, we examined the structural 
variation of NPs in serum using a size exclusion column. Both serum-treated (2h in FBS) and non-
serum (control, 2h in HBS) samples were fractionated by a Sepharose CL-6B size exclusion 
column,[132, 133] and the NR fluorescence of each fraction was determined. (Figure 2.2 B) 
Indicates that NR-containing nanodisc after being incubated in HBS saline (in the absence of FBS) 
were eluted from fractions 16 to 25 (guided by the dotted red curve). It should be noted that in the 
presence of FBS, a sharp fluorescence signal was observed in fractions 10 to 13, presumably 
contributed from the proteins in FBS (guided by the solid blue curve). The nanodiscs after 
incubation with FBS were eluted in a slightly wider spectrum (guided by the red dotted line from 
fractions 12 to 25). A parallel experiment was also carried out using NBD-PC labeled NPs (both 
nanodiscs and vesicles). The results in (Figure 2.4) show similar fractionation patterns as those of 
NR labeled NPs. Both fluorescence measurements and fractionation experiment demonstrate the 
high stability of both NPs in the presence of serum proteins.  
 
Figure 2-3. The fluorescence of NR encapsulated ND after being incubated in with FBS serum and 
with HBS (control) at 37˚C for 24 hours. Absorbance was measured at different time points. 
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Also, known aliquots from various fractions were analyzed for inorganic phosphorus (Pi) as well 
as Nile Red or NBD fluorescence in triplicate, and the fluorescence associated per Nmol Pi was 
determined.[140]  
To assess any non-specific contributions from the FBS, control samples (without nanoparticles) 
containing 1:1 ratio of FBS/HBS (v/v) were also fractionated on the column. The fractions 
corresponding to nanodiscs and vesicles elution were analyzed for fluorescence and Pi (F: Pi) 
ratios obtained typically from fractions 19-21 of the nanodiscs or vesicles. As seen in Table 2.2, 
there was non-specific fluorescence attributed to the serum proteins. However, tiny Pi above 
background levels was detected by the high ratios of F: Pi ratios. Our data also suggests that an 
increase in the ratios of F: Pi in FBS incubated nanoparticles is partly due the serum contributions. 
The further detailed analysis will be required to dissect out this effect. 
Figure 2-4. The NBD-PC containing NPs after being incubated in the absence [(i) and (ii)] and 
presence [(iii) and (iv)] of FBS for 2 hours at 37˚C. The nanodiscs are presented in (i) and (iii), 
while the vesicles are (ii) and (iv). 
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Table 2.2. Determination of Fluorescence: Phospholipid (F: Pi) ratios in nanoparticles fractionated 
by size-exclusion chromatography. Values presented are the average (±S.D.) of F: Pi ratios 
obtained column peak fractions (typically fraction 19-21) of the nanodiscs or vesicles. 
 
2.4.3 Nile red profile in chloroform  
It should be noted that the local high NR concentration in one NP is possibly greater than the 
onset concentration of the NR self-quenching. If this occurs together with the leakage of the 
entrapped NR into the aqueous phase, the fluorescence may increase at a lower NR concentration. 
To verify that our experimental condition does not correspond to such scenario, fluorescence 
measurements are also taken in NR/chloroform samples at different NR concentrations (covering 
the highest possible NR/lipid weight ratio ~ 1/1000) because NR does not fluoresce in aqueous 
solutions. (Figure 2.5) also shows a linear fluorescence response with the NR concentration, 
indicating that the NR in NP is below the onset of NR self-quenching concentration in the organic 
environment.  
2.4.4 Cytotoxicity analysis  
To examine the effects of the nanoparticles on cells viability, various concentrations of NPs were 
incubated with CCRF-CEM, KB, and OVCAR-8 cells up to 48 hours at 37˚C. Data presented in 
(Figure 2.6) indicates that the cell viability is not affected by the presence of either nanodiscs or 
vesicles. It further confirms that the presence of NR in the lipids constituting is not toxic to the 
Sample Tested Relative Fluorescence Units/Nmol Pi (F: Pi)  
HBS FBS 
NR ND (water) 17.17±6.21 35.97±6.17 
NR ND (NaCl) 16.40±6.30 35.14±0.03 
NBD ND (water) 22.69±6.30 40.68±3.45 
NBD ND (NaCl) 24.33±5.27 44.25±1.04 
NBD vesicles 24.66±4.30 35.60±2.50 
FBS alone (NR) N.D. 88.29±16.32 
FBS alone (NBD) N.D. 302±52.50 
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cells.  
 
Figure 2-5. (A) The fluorescence of the NR-containing lipid mixtures (Nile Red–to-lipid weight 
ratio = 1/1000) as a function of lipid concentration and (B) The fluorescence of NR in chloroform 
as a function of NR concentration up to 1/1000 by weight. Both indicate linear relationship as well 
as passing through the origin indicative of negligible self-quenching. 
 
Figure 2-6. Cell viability assay: To study the effect of NPs (nanodiscs and vesicles) on the viability 
of cells, cells were incubated with various concentrations of nanodiscs or vesicles for 48 hours (in 
triplicate), and cell viability was determined. Values are expressed as a percentage of viable cells 
where the control samples (i.e., without the addition of nanoparticles) are considered 100% viable. 
The values are averages of 3 measurements (±S.D.). The results were reproducible from two 
independent experiments.                                                                                                                                                                                          
(A) (B) 
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2.4.5 Cellular Uptake of NPs  
 
It has been reported that the cellular internalization of the NPs significantly changes according 
to the cell line.[141] Therefore, three different cell lines, CCRF-CEM, KB, and OVCAR-8 were 
investigated after being incubated with a solution containing either nanodiscs or vesicles. The 
cellular uptake under various experimental conditions was revealed by FCOM and FACS. The 
fluorescence intensity from either FCOM or FACS can be directly correlated with the quantity of 
cellular uptake under the assumption of negligible self-quenching of the fluorophore. (Figure 2.5) 
Shows linear fluorescence response of the NR-containing lipid mixture as a function of lipid 
concentration up to 1.0 mg/ml, indicative of a negligible self-quenching effect of NR. The FACS 
results of CCRF-CEM cells after being incubated with NPs (i.e., vesicles and nanodiscs 
individually) at 37˚C for 2 hours are illustrated in (Figure 2.7), which indicates that the 
internalization of nanodiscs was significantly higher for all three cell lines. The peak represents 
the highest NP population of the specific fluorescence intensity, which is presumably proportional 
to the cellular uptake. The fluorescence peak intensities of vesicles in the cases of CCRF-CEM, 
KB, and OVCAR-8 were 50, 13 and 50, respectively. In comparison to those of the nanodiscs, 
380, 200 and 600, implying that the internalization of nanodiscs is about 7 to 15 times of that of 
vesicles regardless of the cell lines. This observation suggests that nanodiscs are presumably a 
more efficient carrier to deliver molecules to cancer cells.   
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Figure 2-7. Flow cytometry results of cellular uptake: Representative flow cytometry histogram to 
quantitatively assess the uptake of nanoparticles after incubation for 2 hours at 37˚C: the first 
column of untreated cells (controls), the second column for cells treated with vesicles, and the third 
column for cells treated with nanodiscs. Nanoparticles in all cells show lower cellular uptake of 
vesicles as compared with the results of nanodiscs.                                                                                                                      
 
 
The preferred internalization of the nanodiscs was further supported by the FCOM images as 
shown in (Figure 2.8), where all cells exhibited the highest fluorescence in the case of nanodiscs 
as compared to the vesicles. The dataa acquired from FCOM were consistent with the results 
obtained from the FACS indicating that the cellular uptake of nanodiscs by all cells under study is 
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significantly higher than that of vesicles, confirming the strong dependence of internalization on 
morphology.  
 
Figure 2-8. Fluorescence confocal micrographs: Confocal microscopy images of CCRF-CEM cells 
in the first row, the second row, represents KB cells, and the third row shows OVCAR-8 cells. All 
images were taken after incubation with the NR-contained (A) nanodiscs and (B) vesicles, 
respectively, at 37°C for 2 hours. The nuclei of the cells were dyed with Hoechst (blue).  Three 
images were obtained in each case are illustrated: cells with NR (red), nucleus blue (Hoechst), and 
merged (both blue and red). Clear internalization of the NPs is observed. Moreover, the NR 
fluorescence intensity is found lower in the case of vesicles compared to nanodiscs. Scale bar is 
50 µm. 
To estimate the number of NPs being internalized in the cells, the ratio of NPs associated with 
the cells to those which remained in solutions were investigated through fluorescence. (Figure 2.9 
A) Shows the fluorescence of the total amount of NP dispersion before their incubation with the 
CCRF-CEM cells and the fluorescence remained associated with the cell pellets obtained from the 
centrifuged cells after being incubated with NPs. The initial fluorescence values of the nanodisc 
dispersion are found to be similar to that of the vesicle dispersion, indicating that the morphology 
of NPs has no effect on the fluorescence intensity. In the case of NP concentration applied (i.e., 
1.0 mg/ml), 19.2% of the original nanodiscs fluorescence was found associated with the CCRF-
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CEM cells, while only 8.4% of the initial fluorescence associated with the cells in the case of 
vesicles under the identical experimental conditions. The result of the morphological dependence 
on lipid concentration is shown in (Figure 2.9 B), suggesting that the difference in uptake increases 
with increased NP concentrations (i.e., 1.0 mg/ml shows more uptake compared with 0.5 mg/ml 
and 0.25 mg/ml).  
 
Figure 2-9. Quantification of the uptake: (A) The fluorescence of the 1.0 mg/ml nanodisc and 
vesicle dispersions (blue) as well as the fluorescence from the cell dispersions after the incubation 
with the nanoparticles for 2 hours (green). (B) The ratios of fluorescence readout from the re-
dispersed cell suspension to that of NP dispersions as a function of lipid concentrations.   
The results shown in (Figures 2.7,2.8, and 2.9) lead to the same conclusion that the cellular 
uptake of nanodiscs is higher than that of vesicles in all three cell lines presumably. A plausible 
speculation is that larger surface contact area is anticipated for discoidal morphology, providing a 
better opportunity for the NPs to interact with reasonably flat cell membranes.[46, 47, 142]  While 
vesicles interact with the cell surface through the contact point (instead of the contact surface), 
thus significantly reducing the cellular uptake. Moreover, FCOM at different depths of the cell 
(Figure 2.10) indicates that a good portion of nanodiscs was indeed internalized in the cell.  
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Figure 2-10. The FCOM of a CCRF-CEM cell being incubated with NR-containing (A) nanodiscs 
and (B) vesicles (NR-to-lipid weight ratio = 1/1000), respectively over a range of depths from 0 
to 7 µm. 
2.4.6 Intactness of Nanodiscs before the Uptake 
It was speculated that NR might dissociate from the nanodiscs before the cellular uptake. 
Therefore, the intactness of the NR-containing nanodiscs is one of the research interests, providing 
the knowledge of the transfer mechanism of NR from nanodiscs to cells. To substantiate our 
observations and rule out the possible contributions of NR which was not entrapped by the 
nanodiscs, the cellular uptake studies of both NR and NBD-PC -labeled NPs were performed. 
Since NBD-PC can be well integrated into the DPPC lipid bilayer, by using different filters to 
allow individual color (red or/and green), we could identify the relative locations of NR and NBD-
PC. The secure colocation of these two dyes indicates that the NR did not dissociate from the 
nanodiscs during the cellular uptake process (Figure 2.11).  
(A) Nanodiscs 
(B) Vesicles 
0 m 3 m 5 m 7 m 
0 m 3 m 
5 m 
7 m 5 m 
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Figure 2-11. The fluorescence micrographs of CCRF-CEM cells after being incubated with both 
NR and NBD-PC containing nanodiscs under different configurations: (a) bright field, (b) red 
channel, (c) green channel and (d) both red and green channels. Strong colocation of NR and NBD-
PC was observed. 
2.4.7 Energy-Dependent Mechanisms of NPs Uptake 
To advance our understanding of the NP uptake mechanism, several experiments were also 
conducted at 4°C. Presumably, the energy-dependent uptake would be obstructed due to the 
rigidity of the membrane resulting in inhibiting the passive internalization and effectively 
suppressing the endocytosis.[143] (Figures 2.12 A and B) Illustrate the fluorescence confocal 
microscopic micrographs and FACS results of CCRF-CEM cells after being incubated with 1.0 
mg/ml vesicles or nanodiscs at 37 or 4°C for 2 hours. In the case of vesicles, greater cellular uptake 
was observed at 37°C than that at 4°C, suggesting strong energy dependent mechanisms of the 
vesicular uptake. Interestingly, the parallel experiment for nanodiscs only showed a slight decrease 
(< 10%) at 4°C in comparison to 37°C, suggesting that the cellular uptake of nanodiscs may follow 
a different mechanism from the energy-dependent endocytosis. Further investigation on possible 
mechanisms of the endocytosis of these two NPs was also taken to provide insights to the 
(a) (b) 
(c) (d) 
 25m  25m 
 25m  25m 
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differences in the cellular uptake as described in the following section. 
 
 
Figure 2-12. Energy-dependent uptake at 4˚C: The FACS and FCOM results of the energy-
dependent cellular uptake after incubating CCRF-CEM cells with (A) vesicles and (B) nanodiscs 
at 37˚C (dark blue) and 4˚C (light blue) for 2 hours. The insets are the fluorescence confocal 
micrographs of CCRF-CEM at 4˚C.          
2.4.8 Mechanisms of Uptake 
Six pharmacological inhibitors (listed in Table 2.1 in the “Methods Section”) were employed to 
investigate four cellular uptake mechanisms of both NPs. Specifically, chlorpromazine causes a 
reduction in clathrin adaptor complex protein from the cell surface and thus blocks the clathrin-
mediated pathway.[144] Filipin III leads to the disruption of caveolar pits by inducing aggregation 
of cholesterol in the cell membrane.[144] Three reagents, Amiloride, wortmannin or cytochalasin 
D were individually applied to the cells to block the membrane ruffling and 
macropinocytosis.[144] Finally, nocodazole obstructs microtubule polymerization leading to 
vesicular transportation inhibition.[145]  
Individual inhibitor concentrations were adjusted to achieve a minimum of 90% cell viability over 
2 hours of incubation based on several previous protocols, and the results are presented in (Figure 
2.13). 
(A) (B) 
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Figure 2-13. Viability assay to study the effect of inhibitors on cell viability after 2 hours of 
incubation. The data present a percentage of control sample which was not incubated with the 
inhibitors. 
 The FACS results of both NPs after incubation with CCRF-CEM cells are shown in (Figure 
2.14). Evidently, both clathrin- and caveolae-mediated endocytosis were the major internalization 
pathways for both NPs. However, about 20% of nanodiscs were also internalized through 
macropinocytosis pathway and microtubule-mediated transportation, presumably attributed to the 
morphological variation. This observation is consistent with a recent report on the enhanced 
cellular uptake of disk-like hydrogel NPs in different cell types compared with those NPs of other 
shapes through the macropinocytotic pathway.[141] Another study also suggests that NPs of 
asymmetric shapes (i.e., worm-like micelles and cylinders) have a higher level of internalization 
through the macropinocytotic pathway than spheres.[142] Moreover, our result suggests a much 
lower cutoff size for the cellular uptake of vesicles than 200 nm as previously reported.[142] The 
results of pharmacological inhibitor provide the insight to the origin of the morphologically 
dependent mechanisms of cellular uptake. Multiple uptake mechanisms in addition to clathrin- and 
caveolae-mediated endocytosis are found for nanodiscs rather than vesicles. It also implies that 
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macropinocytosis and vesicular transportation may not be affected by low temperature considering 
(Figure 2.12). Therefore, the enhanced cellular uptake of nanodiscs is presumably due to the 
additional macropinocytosis and microtubule-mediated transport mechanisms. 
 
 
Figure 2-14. Mechanism of uptake: Median fluorescence as the CCRF-CEM cells incubated with 
the NPs (nanodiscs and vesicles) in the presence of various inhibitors. The uptakes of both NPs 
were suppressed in the presence of Chlorpromazine and Filipin III, while the uptake of vesicles 
was not affected by the other inhibitors unlike that of nanodiscs being suppressed in all cases. 
 
2.5 Conclusion  
This work first demonstrates uniform-sized nanodiscs and nanovesicles can be composed of the 
lipid mixture with identical chemical composition, enabling our study on the morphological 
dependence of the cellular internalization with no bias. It is evident that the morphology of 
nanoparticle plays a critical role in the cellular uptake of self-assembled lipid nanostructures.  
These NPs are structurally stable in the presence of serum and do not show cytotoxicity effect. In 
all cases (CCRF-CEM, KB, and OVCAR-8 cancer cell lines) nanodiscs illustrate significantly 
42 
 
 
higher cellular uptake than that of vesicles under the same conditions. Based on the study of 
endocytic mechanisms, the enhancement is presumably attributed to two main factors: (1) the 
larger surface contact area for the nanodiscs to interact with the cell membrane than that of the 
vesicles and (2) multiple pathways of cellular internalization (including macropinocytosis and 
microtubule-mediated transport) other than the typical clathrin- and caveolae-mediated 
endocytosis utilized by the vesicles. This study suggests a potential strategy regulating cellular 
internalization of nanoparticles by their morphological differences.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
 
Chapter 3. Effect of Folate-Targeted Molecule on the Nanoparticles’ Rate of 
Penetration into Cancer Cells 
Abstract  
 
Targeted therapies are developing as an ideal strategy for the treatment of cancer. Evaluating the 
impact of a high-affinity targeting ligand on the rate and extent of cancer cells penetration of 
different morphology of nanomedicine was performed. We have used fluorescence-activated cell 
sorting (FACS) and fluorescence confocal optical microscopy (FCOM) to quantitate the uptake of 
cancer cells of lipid-based self-assembles decorated with polyethylene glycols (PEG)-folate 
nanoparticles (NPs) prepared in two different shapes (discs and vesicles). We demonstrate that 
increasing of the cellular uptake of the discoidal folate NPs compared with the uptake of the 
vesicular and none conjugated NPs. Ligand Targeting eventually leads to increased cell 
accumulation, with endocytosis of the targeted nanocarriers contributing to enhanced delivery. 
Although, the results of the in vivo study on KB tumor-bearing mice by the Caliper IVIS system 
followed the same trend of the in vitro cell study were folate disc > folate vesicle > none folate 
disc > none folate vesicle, however, they were not as significant as the one conducted in the 
monolayer KB cells. Because the effects of nanocarrier shape and targeting ligand are 
interconnected and complex, we suggest that these parameters must be carefully optimized for 
each nanocarrier to ensure optimal drug delivery.  
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3.1 Introduction 
Nanoparticles (NPs) have been widely used as biodiagnostic and pharmaceutical carriers 
to enhance the efficacy of different applications. To date, three generations of NPs have been 
engineered for biomedical applications. The first generation of nanomaterials was modified with 
non-stealth surface chemistries and used in experiments to assess cell uptake and toxicity.[146, 
147] The main focus of these materials was to determine the effects of surface charge.[148, 149] 
Consequently, second-generation nanomaterials are characterized by two important design 
concepts: stealth and active targeting. For the first and second generations, although water 
solubility, biocompatibility and being stealth for the immune system of the body have been met, 
they still need to address issues such as dynamic properties, theranostic abilities, overreliance on 
passive targeting and finally limitations on shape, size and charge adjustments. The third 
generation shifted the paradigm of design to “intelligent” platforms that should improve targeted 
compound delivery, where based on the final approach, a broad range of carrier properties can be 
modified.[150] 
In regards to cancer treatment or diagnosis, several important properties of NPs are 
desirable such as high biocompatibility, long in-vivo circulation half-life, high accumulation at 
cancer tissues and high loading drug/diagnostic capacity. Significant attention has drowned to a 
variety of nanocarriers, such as liposomes,[151] solid lipid NPs,[152] polymeric micelles,[153] 
dendrimers, and aptamers[154] indicating great potential for in vivo applications. That is due to 
their great drug carrying capacity, passive accumulation in malignant and inflamed tissues, long 
circulation times, and adaptability to multiple functions [153, 155].  
Recently, it has been proven that both size and shape can also play a crucial role in cellular 
uptake. The gaps between endothelial cells of the leaky vasculature in the tumor site allow 
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nanostructures to enter a tumor through a mechanism known as the enhanced permeability and 
retention (EPR) effect [38, 56]. The efficiency of this process depends on the physicochemical 
characteristics of the nanoparticles, including both size and shape.  It has been established that 
spherical particles of 20-100 nm in diameter proven to show the optimal range of size for 
enhancing the accumulation of NPs due to the EPR effect [10, 156]. However, different EPR 
effects have been reported to non-spherical nanostructures (i.e., nanorods) due to the variations of 
in vivo hydrodynamic behaviors such as circulation, transport in blood flow, and extravasation into 
the tumor [157, 158]. 
Further, NPs’ shape directly influences uptake into cells. For particles larger than 100 nm, 
rods show the highest cellular uptake, followed by spheres, cylinders, and cubes in several types 
of research [159, 160]. In studies with sub-100-nm nanoparticles, spheres show a definite 
advantage over rods [146, 161] and increasing the aspect ratio of nanorods seems to decrease total 
cell uptake. However, among various shapes, there are very limited studies on discoidal shape. 
Therefore, here we focused on creating sub-100-nm NPs with discoidal shape versus the excellent 
shape based on these studies, which is 50 nm spherical carrier to study in this research. 
 Another important issue, which is commonly overlooked, is the scalability of the NPs. 
Recently low-polydispersity, spontaneously-forming lipid-based nanodiscs (~30 nm in diameter 
and 5 nm in thickness) composed of long- and short- chain lipids [131] are found capable of 
entrapping hydrophobic molecules and have a robust formation/assembly mechanism [42, 43]. The 
platform allows large-scale nanomanufacturing of the NPs. A nanodisc-to-nanovesicle structural 
transition also takes place as the long-chain lipid undergoes from low-temperature gel (order) to 
high-temperature L (liquid disorder) phase. Both nanodiscs and nanovesicles maintain uniform 
dimensions. At low lipid concentrations, the nanovesicles irreversibly form and would not revert 
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to nanodiscs even when the long-chain lipid become gel phase as lowering the temperature below 
the melting point [43-45]. These properties allow us to produce different low-polydispersity 
morphologies from using identical chemical compositions [43].  
However, lack of specificity with passive targeting by nanoparticles is a major drawback 
with this approach. Therefore, it is of critical importance to develop a more accurate and active 
system that could target to the tumor, enhance intracellular uptake, and minimize the NPs 
distribution in healthy tissues. A reasonable approach to achieve these goals is to utilize specific 
interactions between receptors on the cancer cell surface and targeting conjugated to the 
nanocarriers [162]. Some ligands, such as folate and transferrin, can substantially increase site-
specific targeting [163, 164]. In particular, folate has arisen as an ideal targeting ligand for selective 
delivery of attached imaging and therapeutic agents to the tumor site. The efficacy of folic acid in 
these applications has emerged primarily from its simplicity of conjugation to different NPs, the 
high affinity of binding to folate receptor (FR) (Kd ~ 10-9 M) [165], and the extensive distribution 
of its FR in a different portion of human cancers [166-168].  
On the other hand, PEGylation of nanoparticle surfaces increases their blood half-life and 
create long-circulating “stealth” nanoparticles with improved accumulation in the target tissue, yet 
these properties also depend on a nanoparticle’s shape, size, and surface chemistry.  
Furthermore, it has been shown that nanoparticles with a positive charge can perturb the 
cell membrane potential, causing Ca2+ influx into cells and the inhibition of cell proliferation.[169] 
While binding of negatively charged nanoparticles to a lipid bilayer causes local gelation, whereas 
binding of positively charged nanoparticles induces fluidity. On the other hand, blood half-life is 
highest for neutral and slightly negative nanoparticles.[169, 170] Positively charged nanoparticles 
are cleared most quickly from the blood and cause several complications such as hemolysis and 
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platelet aggregation.[159, 169] Therefore, since our platform is capable of being adjusted to have 
defined surface charge, we have done the synthesis in a way to keep the surface charge slightly 
negative for all the samples. 
In this work, we are investigating the impact of folate addition as a targeting molecule on 
the enhancement of the cancer cellular uptake of both discoidal and vascular lipid-based self-
assembly NPs. The size of both nanostructures was confirmed via dynamic light scattering (DLS). 
Fluorescence-activated cell sorting (FACS), and fluorescence confocal optical microscopy 
(FCOM) were used to quantify and visualize the cellular uptake of folate-conjugated NPs, 
respectively. 
3.2    Materials and methods 
3.2.1 Materials  
Dipalmitoyl phosphatidylcholine (di-16:0, DPPC), dipalmitoyl phosphatidylglycerol 
(DPPG), dihexanoyl phosphatidylcholine (di-6:0, DHPC), polyethylene glycol (PEG2000)-
conjugated distearoyl phosphoethanolamine (DSPE-PEG2000), and folate polyethylene glycol 
conjugated distearoyl phosphoethanolamine (DSPE-PEG2000 Folate) were purchased from Avanti 
Polar Lipids (Alabaster, AL, USA) and used without further purification. Nile Red (NR), 
phosphate buffered saline (PBS) powder were purchased from Sigma-Aldrich (St. Louis, MO). 
Sepharose CL-6B was purchased from GE Healthcare (Pittsburgh, PA, USA). Cell Titer Blue kit 
was purchased from Promega (Madison, WI, USA).  Folate deficient RPMI Medium (FD-RPMI), 
Dulbecco's Phosphate-Buffered Saline (DPBS), and Hoechst 33342 were purchased from Life 
Technologies (Grand Island, NY, USA). 
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3.2.2 Cells  
FR expressing human cervix carcinoma KB cells were continuously grown as monolayers 
using (FD-RPMI) containing 10% heat-inactivated fetal bovine serum at 37 °C in a 5% CO2 and 
95% air humidified atmosphere. 
3.2.3 Synthesis of Folate Conjugated Lipid NPs of Different Shapes 
(DPPC), (DPPG), (DHPC), (DSPE-PEG2000), (DSPE-PEG2000 Folate), and (NR) were used 
for NPs preparation. The molar composition of the mixture follows DPPC/DHPC/DPPG/DSPE-
PEG2000/DSPE-PEG2000 Folate/NR = 66.58/25.1/3.76/4.5/0.5/0.002. All components of the 
required weights were first homogenized in chloroform. After the removal of the solvent by a 
vacuum oven, the dried samples were then re-dispersed in filtered D.I. water to make stock 
suspensions with a total lipid weight concentration, Clp of 10 wt%.  After successive vortex and 
temperature cycling between 25 and 70°C, the stock dispersions were then progressively diluted 
at room temperature to Clp = 1.0 mg/ml with phosphate buffered saline (PBS) solution. Vesicles 
were formed by increasing the temperature of 1.0 mg/ml discs’ solution to 55°C for several hours.  
3.2.4 Nanoparticles Characterization (Thanks to Armin Rad) 
3.2.4.1 Small angle X-ray scattering  
Nanostructures were dissolved at a concentration of 10 mg/ml in distilled water. Before SAXS 
measurements, the supernatants were put in an ultrasonic bath for 30 min and vortexed for 10 
minutes. For each experiment, 70 µl of the solution was transferred to Brucker Company standard 
quartz capillary of 1.5 mm path length, and the background of each sample was measured 
separately before each experiment. Both scattering and transmittance of each sample were 
measured separately. Small angle X-ray scattering (SAXS) measurements were conducted at a 
Bruker NanoSTAR instrument. X-ray was generated by a Turbo (rotating anode) X-ray source 
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(TXS). A wavelength, λ of 1.542 Å was chosen by Cu-kα using the Göble mirror. A pair of 
“scatters” pinholes with diameters of 500 and 350 μm, respectively, was used for collimation. The 
2-D intensity data was collected by a MikroGap VÅNTEC-2000 detector with a sample-to-
detector distance of 108 cm to cover a scattering vector, q range (𝑞 ≡
4𝜋
𝜆
𝑠𝑖𝑛
𝜃
2
, where θ is the 
scattering angle) from 0.007 to 0.25 Å-1.  
The results will be shown as an absolute scaled intensity as a function of q = 4л sin (θ/2)/λ 
where θ is the scattering angle and λ is the X-ray wavelength. Radial averaging and q-conversion 
of data were performed using the standard software at the beamline. Absolute scaling, i.e. 
expressing intensities as scattering cross-section per sample volume in units of cm-1, was 
conducted using BSA as a standard.  
3.2.4.2 Dynamic Light Scattering 
Size and population distribution of folate and none folate nanodiscs and vesicles were 
determined by  DLS with 633 nm laser beam. All studies were carried out at 15°C for folate 
conjugate nanodiscs and 25°C for nanovesicles. The samples were dissolved in ultrapure distilled 
filtered water to 0.1 wt%, aged for five days and vortexed before each measurement. The results 
were the average of 10 times measurements. 
3.2.5 Viability and cytotoxicity assay 
Cytotoxicity against KB cells of folate nanoparticles (discs and vesicles) was assessed by 
Microculture Tetrazolium Assay (MTT) assay and compared with none folate NPs (disc and 
vesicles). Briefly, KB cells were seeded in 96-well plates at a density around 5000 cells/well. Cells 
could adhere for 24 h before the assay. Cells were exposed to a series of doses (range from 0 mg/ml 
as a control to 1.6 mg/ml) of folate or none folate nanoparticles in (FD-RPMI) medium at 37 °C. 
After incubation with cells for 24 h, 25 μl of MTT indicator dye was added to each well and the 
50 
 
 
cells were incubated for another four h at 37 °C in the dark. The absorbance was measured at 570 
nm using a microplate reader. The value was normalized to the control value (untreated cells) to 
obtain percentage cell viability. 
3.2.6 Evaluation of the effect of folate targeting on the cellular uptake 
KB cells were plated in a six-well plate at a density of 50 000 cells/well and allowed to adhere 
overnight. For analyses of NPs uptake, 20 μL of 1 mg/mL folate nanodiscs, nanovesicles, none 
folate nanodiscs (control), and none folate nanovesicles (control) were added to each well and 
incubation was carried out for two h at 37 °C. Following incubation, wells were washed thoroughly 
with DPBS to remove unbound ligand, after which cells were removed from the plate by trypsin, 
centrifuged to form a pellet, and resuspended in cold (4 °C) DPBS to block further FR trafficking. 
Fluorescently labeled NPs in all cell samples were quantitated on a Becton Dickinson FACS 
Caliber flow cytometer. Ten thousand cells were counted from each sample, and three samples 
from each treatment condition were evaluated. CellQuest software was used for data collection 
and analysis. 
3.2.7 Confocal microscopy for uptake visualization (Thanks to Armin Rad) 
The visualization of the folate NPs internalization to KB cells was done by a Nikon A1R 
confocal microscope using a 60 x oil immersion lens. Image acquisition was performed by Nikon 
Elements Ar software. The pre-imaging incubation procedure followed the same conditions for the 
FACS quantification except that cells were not removed from the well by trypsin. The intensity of 
the laser beam and the photodetector sensitivity were kept constant to compare the relative 
fluorescence intensities between experiments. 
3.2.8 Mechanism of uptake 
FA receptors in KB cells were blocked by adding folic acid to verify that the uptake 
51 
 
 
mechanism of folate conjugated NPs is following the folate receptor-mediated endocytosis. In 
brief, 1mM of folic acid was added to each well after plating 50 000cells/well in a six-well plate, 
and incubated for 30 minutes at 37 °C. Then both folate and none folate NPs (discs and vesicles) 
were added to each well and incubated for two h at 37 °C. Following incubation, wells were 
washed twice with DPBS and cells were removed from the plate by trypsin, centrifuged, and 
resuspended in cold (4 °C) DPBS to block further FR trafficking. The quantification was 
performed using FACS and confocal microscopy.  
3.2.9 Intracellular localization study (Thanks to Dr. Lai and his group) 
To follow intracellular trafficking of nanoparticles, 1×105 KB cells were seeded on 15 mm 
glass coverslips and incubated at 37°C for 24 h. Then folate or none folate NPs (discs and vesicles; 
lipid concentration: 0.1%) were added to cells and incubated for six h. After incubation cells were 
treated with Lysotracker Green DND-26 (the guideline was provided by Invitrogen) for 30 min, 
followed by washing three times with HBSS buffer and fixing with 4% paraformaldehyde at room 
temperature. The coverslips were mounted onto a glass slide. Then, the co-localization of 
nanoparticles within lysotracker-labeled cellular compartments was examined by confocal laser 
scanning microscopy (CLSM; Leica-SP5, Leica Microsystems Heidelberg GmbH, Germany). The 
colocalization ratio of nanoparticles within Lysotracker was quantified by Metamorph software. 
3.2.10 Tumor penetration and accumulation of folate lipid NPs in vivo (Thanks to Dr. Lai 
and his group) 
Non-invasive in vivo imaging system (IVIS) experiment was approved by the Institutional 
Animal Care and Use Committee of the National Chung-Hsing University. Female athymic nu/nu 
(nude) mice (ages 6-10 weeks, LASCO) were sterilely inoculated subcutaneously in the right flank 
with 1×107 KB cells. Two hundred microliter of folate or none folate NPs (discs and vesicles; lipid 
52 
 
 
concentration: 2%) were intravenously injected via tail vein when the tumors reached a volume 
around 500-1000 mm3. Images were recorded by the Caliper IVIS system (excitation: 535 nm, 
emission: 600 nm) at different time points after injection. The fluorescence images were quantified 
by Living Image software. 
3.3 Result and discussion  
3.3.1 Nanoparticle Characterization  
 SAXS can provide an empty core-shell architecture of the designed NPs. This technique is 
very sensitive to the electron density distribution in the structure of nano-assemblies averaged in 
time. SAXS data of 1.0 wt.% of folate nanodisc, folate nanovesicle, nanodisc, and nanovesicle and 
were expressed by the scattering intensity as a function of scattering vector, q (defined as 
4лsin(Ө/2)/λ, Ө and λ being the scattering angle and wavelength, respectively) as shown in (Figure 
3.1). Monotonic decays with different slopes were observed in the SAXS patterns. Both nanodisc 
curves show extra oscillation-like decay at 0.03 Å-1 < q < 0.05 Å-1. The main peaks for both were 
at around 0.12 Å-1 which confirms the bicelle structures in them. The overall diameters from SAXS 
data are the thickness of the bicelle structure while DLS showed the hydrodynamic diameters of 
the nanodisc nanostructure.  
Lipid bilayer can be considered as a lipophilic core (hydrocarbon chains) being sandwiched 
by two shells (hydrophilic phosphatidylcholine headgroups). Since phosphate group has the 
highest electron density in the system – greater than those of hydrocarbon tails and water, the 
electron density profile across the bilayer (i.e., water-headgroup shell-hydrocarbon core-
headgroup shell-water) can be approximated by a “square well”. Thus, the SAXS pattern leads to 
a broad peak corresponding to the correlation length of headgroup-headgroup distance as shown 
in (Figure 3.1). Moreover, the slope at low q region could also infer possible morphology of the 
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lipid aggregates.  
 
 
Figure 3-1. SAXS characterization of nanodiscs and nanovesicles. 
 
 Moreover, in both nanodisc samples, a transition of slope from q-2 to q-4 was found indicating 
that the lipid aggregates were presumably in the planar bilayered structure for both cases. As 
mentioned above, the high q peaks were observed in both nanodiscs which correspond to the 
distance between phosphate headgroups. For significant high electron density of headgroup over 
those of hydrocarbon core and water, the distances between phosphate headgroups can be 
estimated by the peak position of qpeak. That is: 
 
Since 
𝜆 = 𝑑 ∗ sin (
𝜃
2
) for Bragg condition 
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𝑞𝑝𝑒𝑎𝑘 = 4 ∗ 𝜋 ∗ sin⁡(
𝜃
2
)/𝜆 
So 
𝑑 = 2 ∗ 𝜋/𝑞𝑝𝑒𝑎𝑘 
At 55°C where vesicles will form, SAXS were also conducted to investigate how folic acid 
molecules would affect the transformation from nanodisc to vesicles. The slope of the curve for 
both nanovesicle samples were q-2 which could prove that the particles were vesicles composed of 
the bilayer.  
Furthermore, one of the most significant advantages of SAXS is its capability of 
differentiating the locations of atoms regarding their distinct electron densities, which is reflected 
by different scattering intensity at various q ranges.  
To further explain the SAXS pattern, we employ a core-shell discoidal (CSD) model for 
nanodisc samples, and one-core-three-shell spherical (CSS) model for nanovesicle samples 
(supporting information) as reported in a recent literature.[8] Each model is described by up to 
nine independent parameters– the shells thicknesses (which may consist of radial and facial 
thicknesses, trim and ts,norm), the core thickness (tcore) and radius (Rcore), the electron densities of 
solvent (which here is equal to electron density of water, w), shell ( may consist of rim’s, rim, and 
faces’, s,norm) and core core (core), as well as polydispersity of the core radius (p = 
𝜎𝑅
〈𝑅𝑐𝑜𝑟𝑒〉
, R and 
<Rcore> being the standard deviation and average of Rcore, respectively).  
Using these models and the same values of electron densities as reported in the literature,[150, 
171] we can best fit the SAXS data with excellent agreement (Table 3.1). The results of fittings 
validate the applicability of the models as well as provides us the variations in size and electron 
density of the nanocarrier after the addition of the folic acid to verify the probable changes 
regarding the shape, diameter and so on.  
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 rim, ×10-6 Å-2 trim, Å core, ×10-6 Å-2 tcore, Å Rcore, Å 
Nanodisc 9.8 23.5 8.5 26.6 101 
Folate Nanodisc 9.8 23.9 8.7 28.9 115 
Nanovesicle - - 8.4 44.6 232 
Folate Nanovesicle - - 8.5 47.1 239 
Table 3.1. The best-fitting parameters obtained from the SAXS data of the nanocarriers with 
invariant ts,norm (= 14.9 Å), w (= 9.40 x 10-6 Å-2) and s,norm (= 1.06 x 10-5 Å-2).  
  
 These observations were confirmed by DLS results as shown in (Figure 3.2) which presented 
the monodispersed lipid nanostructures has two different size ranges, based on the applied 
temperatures. The samples which have been under heating process, nanovesicle and Folate-
nanovesicle, the hydrodynamic radius is ~20 nm. Furthermore, the folic acid conjugated to the 
surface increased the size slightly which might be due to the laser scattering around the added 
molecules. On the other hand, the radius sizes of the nanodisc samples are below 10 nm which is 
in consistency with the SAXS results. 
Most importantly, both DLS and SAXS data clearly indicated the absence of nanoparticle 
aggregation in a solution. The low-q SAXS scattering intensity of nanodisc samples increased in 
comparison with that of nanovesicles as shown in (Figure 3.1) and the contrast was significantly 
enhanced.  
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From DLS results it was clear that the size of lipid structures was changed after transformation 
to vesicles. However, DLS could only provide the average size information for nanodisc samples 
based on spherical assumption.  
 
These results are promising for the application of the nanostructures since it has been shown 
that our liposomes have diameters between 46.4 to 47.8 nm, which is within 30 to 50 nm range 
which is the “sweet spot” for nanocarriers.[159, 169] In this size range, not only the nanostructures 
meet the EPR criteria, but also the ligand density is optimal.[169] 
Although in the range of 50-100 nm, EPR effect can be observed, but above 50 nm, nanoparticles 
bind such many receptors that uptake is limited by the redistribution of receptors on the cell 
membrane via diffusion to compensate for local depletion. Nanoparticles greater than 50 nm bind 
Figure 3-2. Size distribution of folate nanodiscs and nanovesicles. The hydrodynamic radius, RH 
of folate conjugated NPs was 10 nm for nanodiscs and 21 nm for nanovesicles. 
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with high affinity to a significant number of receptors and may limit the binding of additional 
nanoparticles. Mathematical modeling of this phenomenon has demonstrated that optimal 
endocytosis occurs when there is no ligand shortage on the nanoparticle and no localized receptor 
shortage on the cell surface.[169, 172] On the other hand, the nanoparticles smaller than 20 nm 
penetrate deep into the tumor tissue but are not retained beyond 24 h. It also has been shown that 
even adding a targeting moiety on the surface of these nanoparticles does not appear to increase 
accumulation inside the tumor or change biodistribution. They are quickly eliminated from the 
body because they can be excreted by the kidneys.[172, 173] 
3.3.2 Viability and cytotoxicity assay 
(Figure 3.3) summarizes the outcomes of MTT assay where the cell proliferation counts were 
obtained after 24 hours of incubation with KB cells. The results were compared to the control cells 
which were incubated in the buffer in the absence of NPs. No toxicity effect on KB cells up to 1.6 
mg/mL (the lipid concentration) was observed in all cases of NPs. The results indicate that all the 
components making up the NPs are biocompatible.   
Figure 3-3. The summarized result of MTT viability test on KB cells after being exposed to a 
solution containing different concentrations of folate or non-folate NPs for 24 hours. 
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3.3.3 The effect of folate targeting on the cellular uptake 
FACS was used to evaluate the cellular uptake of NPs by KB cells. (Figure 3.4) shows the 
FACS results of four different NPs (bicellar discs, folate discs, vesicles, and folate-vesicles) under 
the same condition, lipid concentration, and Nile red-to-lipid molar ratio. Each experiment was 
repeated at least three times. The cellular uptake level of NPs shows a clear dependence of targeting 
folate FACS data of the cellular uptake of folate and non-folate NPs by the KB cells after 2 hours 
of incubation at 37˚C.  
 
The result shows that the uptake level follows: folate-discs > folate-vesicles > discs > vesicles. 
and particulate morphology: folate-discs > folate vesicles > discs > vesicles. The uptake of folate 
discs was higher than that of folate vesicles by ~ 2-3 folds, consistent with our previous report on 
Figure 3-4. FACS data of the cellular uptake of folate and non-folate NPs by the KB cells after 
2 hours of incubation at 37˚C. The result shows that the uptake level follows: folate-discs > 
folate-vesicles > discs > vesicles. 
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the morphological dependent of the cellular uptake of lipid-based self-assembled non-folate NPs 
(i.e., nanodiscs and nanovesicles). The addition of DSPE-PEG2000 folate on the surface of the 
NPs further enhanced the KB cellular uptake by ~7 folds. It has been reported that the uptake of 
monoclonal antibody-coated polystyrene nanoparticles in an experiment on the breast cancer cell 
line was found the highest in the case of rod-like NPs with a size of 367nm in length and 126 nm 
in width. Followed by discs in the size of 236nm in diameter and 88 nm in thickness and the lowest 
for 200 nm spheres.[122]  Our FACS results seem to suggest a similar trend even in a much smaller 
length scale (< 50 nm), further confirming the roles of nano-scaled morphology and targeting 
molecules in the enhancement of cellular internalization. It is also noteworthy that the targeting 
effect, in this case, overwhelms the morphological effect since the folate-vesicles show higher 
efficacy in cellular uptake than non-folate discs do.  
Fluorescence confocal microscopy was also conducted under the same sample condition to 
confirm the FACS results. The optical configuration was identical for all cases. (Figure 3.6 A-D) 
Show the confocal micrographs of KB cells after being incubated with folate discs, discs, folate 
vesicles, and vesicles, respectively, for 2 hours and rinsed twice in DPBS. The outcome is 
consistent with the FACS above result indicating the same sequence in the cellular uptake: folate-
discs > folate vesicles > discs > vesicles.       
 
3.3.4 Mechanism of Enhanced Endocytosis by Folate Targeting 
 
To confirm that the enhanced cellular uptake of folate-conjugated NPs originates from the over-
expressed folate receptor-mediated endocytosis, we performed a similar FACS experiment under 
the same condition above except for free folate (at a concentration of 1.0 mM) being added in the 
cell growth medium.[174] 
60 
 
 
(Figure 3.5) Shows the FACS results of the cellular uptake of folate lipid NPs by the KB cells. 
Compared with the outcome obtained from the medium in the absence of free folate, the cellular 
uptakes were significantly reduced by an order of magnitude, supporting the proposed folate 
receptor-mediated endocytosis. The higher level of cellular uptake of folate nanodiscs than that of 
folate vesicles remains valid even in the presence of free folate consistent with our previous report 
revealing that nanodiscs effectively utilize two more endocytosis (namely, macropinocytosis and 
microtubule-mediated endocytosis) than the vesicles do, independent of the pathway through 
folate receptor.[175] 
 
Figure 3-5. FACS analysis of folate mediated endocytosis. The uptake of folate NPs was reduced 
after the addition of free folate (dark blue) line show the reduction in case of folate discs compared 
to the (pink) line, and (light blue) represent the reduction in case of folate vesicles compared to 
the (green) line.    
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The confocal fluorescence microscopic micrographs (Figure 3.6) where A is compared with 
E and B is compared with F. The results are consistent with the FACS outcome that the presence 
of excess free folic acid in the culture media reduces the uptake of folate NPs.   
 
3.3.5 Intracellular localization study  
The intracellular trafficking of NPs was investigated by labeling with Lysotracker Green 
DND-26 (green). (Figure 3.7) Showed that a lot of none folate NPs (nanodiscs and vesicles) were 
colocalized in lysosomes (nanodiscs: 98.69%; vesicles: 92.42%). It was indicated that none-folate 
NPs entered lysosomes and trapped there at six hr. A study by Mansoori and co-workers 
demonstrated that folate conjugated NPs attached to the folate receptors, followed by uptake 
through a caveolin endocytotic pathway. The drug was released when the pH value of endosome 
Figure 3-6. Confocal micrographs represent the uptake of folate NPs. (A) folate discs, (B) for folate 
vesicles, (C) none folate discs, (D) none folate vesicles, (E) and (F) folate discs and folate vesicles 
after the addition of free folate into culture media. Scale bar is 50 µm. 
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approaches five.[176] Another study by Cuong et al. showed that the uptake of the folate-decorated 
star-shaped PEG–PCL micelle in MCF-7 was via caveolae/lipid raft-mediated endocytosis and 
then folate receptor-mediated endocytosis.[177] In our research, we also observed that the strong 
fluorescence of folate NPs was almost expressed in the cytoplasm. The observation of fluorescence 
in cytoplasm indicated that the folate NPs were internalized by the cells through endocytosis and 
folate NPs were distributed in the cytoplasm after escaping from the endosome and/or the 
lysosome (nanodiscs: 7.91%; vesicles: 29.81%).  
 
 
 
Figure 3-7. Fluorescent images were utilized to assess the colocalization of nanodiscs-Nile red 
with or without FA and vesicles-Nile red with or without FA (Red) with lysosomes using 
Lysotracker (green). The colocalization ratio of nanoparticles within Lysotracker was quantified 
by Metamorph software. Scale bar: 10 μm. 
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3.3.6 Tumor penetration and accumulation of folate lipid NPs in vivo 
The tumor targeting efficiency of the folate and none folate NPs were evaluated in vivo using 
KB tumor-bearing mice by the Caliper IVIS system. Folate disc NPs exhibited a higher tumor 
uptake in comparison with folate vesicle NPs at different time points. The same situation also 
observed in none folate disc NPs and none folate vesicle NPs. The penetration rate and 
accumulation volume of NPs were folate disc > folate vesicle > none folate disc > none folate 
vesicle (Figure 3.8., Table 3.2 and Table 3.3).  
Since the molarity percentage of the charged lipids, DSPE-PEG2000 and DHPC, is fixed 
within the different samples, surface charge cannot be a major parameter to cause these various 
biological responses. Nonetheless, it is worth to mention that since neutral and slightly negatively 
charged nanoparticles have longer circulation lifetimes and less accumulation in the liver, spleen, 
kidneys and lungs, we have chosen the lipids above to provide a marginally negative charge.[159, 
178]  
Additionally, it is well-known that cylindrical and discoidal shapes exhibit unique flow 
characteristics that substantially alter circulating lifetimes, pharmacokinetics, biodistribution, cell 
membrane interactions and macrophage uptake, which in turn affect biodistribution among the 
different organs.[159, 178]  
These results confirm that the nanodisc samples are even more efficient than the spherical NPs 
which were within the optimum range of size and surface charge. Keeping the size of all the 
samples within 30-50 nm range improved their EPR effect as well as having maximum surface 
ligand density for the interaction with the cells.[169, 170] Within the previous size range, the 
excellent shape was introduced to be a spherical shape in previous studies. Spherical nanoparticles 
showed significant better cellular uptake in comparison with other shapes with higher aspect ratios, 
64 
 
 
such as rods.[146, 161] Interestingly, recent mathematical modeling combined with in vitro and 
ex-vivo experimentation demonstrated that discoidal geometries possessed the most favorable 
margination dynamics in the body.[173] However, to the best of our knowledge, discoidal shape 
was not studied in a fair comparison with another shape in an optimization study like this. Hence, 
current results can clearly show this shape, at least for this charge and carrier chemistry, is 
significantly more successful than spherical carriers and potentially can be a promising alternative 
shape for the next generation nanocarriers. 
Likewise, NPs’ geometries affect hemorheological dynamics, cellular uptake and in vivo fate. 
It has been shown that discoidal nanoparticles display unique movement dynamics that favor the 
interaction with vessel wall more than spherical particles.[159, 179] Therefore, the observed 
differences between biological responses to our various samples can be originated from several 
causes. 
 
 
Figure 3-8. In vivo fluorescence images of mice bearing KB tumor. The mice were intravenously 
administered with folate or none folate NPs (discs and vesicles) at 2% lipid, and the fluorescence 
signal was monitored at different time points post-probe administration. 
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Nanodiscs: 0min 10min 30min 1hr 4hr 
FA 5.3041E+10 3.3243E+11 3.1265E+11 2.4921E+11 9.9726E+10 
FA- 1.3151E+10 6.418E+10 6.1226E+10 4.9961E+10 2.6124E+10 
Vesicle:      
FA 3.9885E+10 2.1973E+11 2.0676E+11 1.4999E+11 5.7415E+10 
FA- 2.5601E+10 1.0201E+11 9.1472E+10 6.6584E+10 3.9853E+10 
 
Table 3.2.  Region of interesting in tumor was quantified by Living Image software 
 
 
Table 3.3. Fold increasing of (ROI) in the tumor. 
 
 
  
Nanodiscs:  0min 10min 30min 1hr 4hr 
FA 1 6.27 5.89 4.70 1.88 
FA- 1 4.88 4.66 3.80 1.99 
Vesicle:       
FA 1 5.51 5.18 3.76 1.44 
FA- 1 3.98 3.57 2.60 1.56 
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3.4 Conclusion  
Both in vitro and in vivo results indicate the impacts of morphology and ligand-targeted 
nanoparticle accumulation in cancer cells. The toxicity of the folate and none folate NPs are 
minimal to KB cells. Overall speaking, folate targeting provides an important mechanism for high 
cellular internalization for KB cancer cells. Moreover, our experimental outcome also indicates 
that the NPs with vesicular shape is less efficient in cellular uptake compared with those of 
discoidal shape. However, the shape effect is not as significant as the folate targeting in the cell 
study compared to the animal study.   The penetration rate and accumulation volume of NPs were 
folate disc > folate vesicle > none folate disc > none folate vesicle.  
These findings, besides other research regarding low-polydisperse well-defined 
nanocarriers [159, 169, 178] can alter the EPR paradigm, which has been limited to define the 
effect of particle size in cancer diagnostics and therapeutics, in favor for the more general targeting 
approaches. Accordingly, development of platforms and nanocarriers fabrication processes which 
can create non-spherical shapes may hopefully provide a path to a revolutionary feasible design 
solutions.  
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Chapter 4. Tumor on Chip: A Potential Strategy to Examine the Impact of 
the Design of Lipid Nanoparticles on their Transportation into 3D Ovarian 
Tumor.  
 
 
Abstract 
A key factor in cancer treatment and drug therapy is the development of carriers that can 
proficiently reach targeted cells. Results obtained from nanomedicine studies are mostly based on 
2D cultures which cannot be interpreted to in vivo. In this work, we developed a 3D culture 
microfluidic chamber made of a polydimethylsiloxane (PDMS) for studying nanoparticle 
penetration and transport in ovarian cancer cell–gel cultures. A mixture of cells embedded in a 4- 
arm Poly (ethylene glycol) acrylate (4-arm PEG Acrylate) hydrogel is loaded in the chamber. The 
microfluidic device offers straightforward and rapid fabrication, direct in vitro cell imaging, and 
an easily configurable and controllable microenvironment for different cell culture. To assess the 
application of the device, we studied the transportation of two distinct shapes of fluorescently 
labeled lipid self-assembly nanoparticles, in addition to studying the effect of targeting molecules 
in increasing the penetration of nanoparticles to the 3D cancer cells embedded in the microchannel 
under constant flow conditions. Penetration of nanoparticles was enhanced by targeting to folic 
acid receptors and revealed particle shape restrictions to efficient delivery. This device was 
designed for delivery studies. However, it can be easily modified to be useful for any other 
biomedical applications. 
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4.1 Introduction  
Nanotechnology has emerged as an important tool to be applied in cancer-targeting 
therapeutic and diagnostic. Nanoparticles (NPs) made of a variety of materials in different sizes 
and shapes are the point of interest in many types of research. However, delivery of these 
nanoparticles remains unpredictable because of poor control over the accumulation of carrier 
systems in tumor tissues in vivo.[4] To overcome this problem, a better understanding of how 
nanoparticles (on their size, morphology, and surface modification) enter to the target tumor and 
distribute at the cellular level is required.  
So far, in vivo animal models have been useful for assessing general pharmacokinetics.[80-
82] Also, they have been used to study the effect of different criteria in particles manufacturing 
such as size, shape, surface modifications and the material in use.  However, it has been difficult 
to evaluate the tumor tissue without interruption of lymphatic and blood clearance.[180] Also, it 
is hard to visualize target tissues at the cellular level during animal studies because of the low 
resolution of whole-animal imaging techniques.[83] As a result, our knowledge of the interaction 
between the nano-carriers and the cell is gained from in vitro cell monolayer experiments.[18] 
Information gained from these studies is mostly limited to characterization of the binding affinity, 
uptake, cellular responses and toxicity of the nanoparticles.[46, 54, 74, 75] However, the absence 
of a three-diminution (3D) tissue structure make these findings inaccurate to predict the in vivo 
results.  
A massive number of evidence suggests that the 3D models replicate more accurately the 
actual microenvironment of the tumor compared to the two-dimensional (2D) monolayer cell 
cultures; therefore, the behavior of cells cultured in 3D will reflect more closely the in vivo 
responses.[76-79] Thus, different approaches of in vitro 3D culture models for cancer research 
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have been invented. These methods include but not limited to the multicellular spheroids grown in 
suspension,[86, 114, 181] cells embedded within either naturally derived extracellular matrices 
(ECM) [182-185] or collagen gels.[113, 186] 
A recent approach which offers a highly customizable micro-scale platform to assess 
complex cellular structures has been the focus of researchers. Microfluidic devices are an excellent 
tool to investigate tumor tissue in a relatively natural microenvironment. Microfluidic devices can 
be adapted for different biomedical applications such as cells culture, mimicking the cellular 
microenvironments, and ex vivo tissue evaluation.[11, 93, 187-190] All of these can be done using 
microliter amounts of reagents under controllable flow conditions.[118, 191, 192]  
Based on several in vivo and ex vivo studies, it is well recognized that NP size, shape, and 
surface chemistry can affect tumor accumulation.[18, 46] Several 3D in vitro studies have been 
done to evaluate chemotherapeutic drug diffusion;[109-112] however, the role of drug carriers 
design in tumor accumulation is not well addressed. These studies announced the potential role of 
microfluidics as an approach for the rapid and cost-effective pre-screening of nano-carriers while 
also providing sufficient data to model the transport process before full animal studies.[118]  
As previously mentioned, only a few studies have been done using microfluidic devices to 
evaluate the relationship between nanoparticles physiochemical properties and their penetration 
into the tumor. The focus of these research was on the effect of the nanoparticle size on their 
abilities to overcome the physical factors and barriers that influence their distribution in the tumor. 
[115, 116] The results of these studies suggest that the usage of the microfluidic systems assist the 
evaluation of different NPs in different tumor systems before animal studies.  
Here, we present the design, fabrication, and evaluation of hydrogel cell culture microfluidic 
device that can be used to study nanoparticle penetration and delivery to cancer cells in a 3D matrix 
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under interstitial fluid flow. The device met all essential design criteria for this application, 
including the viable cell culture in a 3D matrix, the imposition of fluid flow through the 3D cell 
culture, and the live cell imaging during perfusion. Moreover, we could proof the feasibility of 
using this device to investigate the effect of shape (discoidal and vesicular) with the addition of 
folic acid (FA) targeting on the penetration of nanoparticle through the hydrogel to 3D ovarian 
cancer cells. 
4.2 Materials & Methods 
4.2.1 Materials 
Microfluidic devices were gently provided by Prof. Pinar Zorlutuna’s group, 4-arm PEG 
Acrylate, Mw 20000, was purchased from JenKem Technology, Allen, TX, USA. The 
photoinitiator, 1-[4-(2-hydroxyethoxy)-phenyl]-2-hydroxy-2-methyl-1-propane-1-one (Irgacure 
2959) was purchased from Ciba, Tarrytown, NY, USA. RPMI-1640 media and phenol-free RPMI-
1640 media were purchased from Life Technologies, Grand Island, NY, USA. 
4.2.2 Cell culture 
OVCAR-8 a human ovarian cancer cells (gently provided by Prof. Xiuling Lu, Department 
of Pharmaceutical Sciences, University of Connecticut) were cultured in a monolayer in RPMI-
1640 media supplemented with 10% FBS and 1% penicillin at 37˚C in 5%CO2 and 95% humidified 
air. Cells grown to pre-confluency were passaged no more than ten times using 0.25% trypsin and 
0.04% EDTA. Before encapsulation in hydrogels, cells were added to the pre-polymer solution 
and mixed gently.  
4.2.3 Fabrication of Microfluidic Devices  
The design and fabrication of the device were performed by our cooperator Dr. Pinar 
Zorlutuna’s group. Devices were fabricated using elastomer polydimethylsiloxane (PDMS) as 
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follow: (a) Rapid Prototyping which included the designing of three microfluidic channels (outer 
channels widths = 1100 µm, the middle channel is 2200 µm) in a Computer-aided design (CAD) 
program: The design transparencies as seen in (Figure 4.1 A) were printed by a commercial printer 
from the CAD files with the design clear and the background ink. Transparencies were used as 
masks in photolithography on negative photoresist (SU-8) spin-coated onto silicon wafers to create 
masters. (b) Molding: a 10:1 mixture of PDMS prepolymer and curing agent (Sylgard 184) were 
stirred thoroughly and then degassed under vacuum. The prepolymer mixture was then poured 
onto the master and cured for one h at 65 °C. After curing, the PDMS replica was peeled from the 
master. (c) Sealing. A PDMS replica and a cover slip will be rinsed in ethanol. The cured mold was 
irreversibly bonded to the coverslip by oxygen plasma treatment and tubing of 1/16 inches. Inner 
diameter was used to connect to syringes pump for cell loading and media injection. (Figure 4.1 
B) represents the fabrication process.  
 
Figure 4-1. The design and fabrication of the microfluidic device. (A) The CAD design of the 
microchannel. (B) The fabrication process using photolithography. 
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4.2.4 Hydrogel Preparation and Cell Encapsulation Process 
20 mg of 4-arm PEG Acrylate 20K (PEG 20K) was mixed with 100 µl of phenol-free RPMI-1640 
media. Also, a 1% photoinitiator (PI) (Irgacure 2959) was prepared by mixing 10 mg PI with 100 
µl ethanol and 900 µl PBS. Encapsulation was done using an equal volume of OVCAR-8 cells 
suspension and pre-polymer solution to give a final concentration of 10 % PEG20K, 0.1 % 
photoinitiator (wt/v, Igracure 2959), and 50 million cells/mL in phenol-free RPMI-1640. Cells and 
prepolymer were mixed, and the microfluidic chambers were filled with the mixture then cross-
linked via UV irradiation for 30 seconds at 6.9 mW/cm2. After encapsulation, hydrogels were 
washed several times with media to remove the uncrossed gel and PI. Then the cells within the 
microfluidic device were incubated under 5 % CO2 at 37˚C. Media was supplemented using a 
syringe pump under a constant flow rate. The cell aggregations and tumor formation within the 
hydrogel were evaluated and measured using Zeiss Axiovert 40 CFL inverted microscope. 
4.2.5 Cell Viability within Hydrogel 
Two methods were used to assess long-term cell viability in the cross-linked hydrogel and the 
microchannel. In the first study, OVCAR-8 cancer cells at a density of 10 million cells/mL were 
encapsulated in 10% PEG20K hydrogels patterned in single-layer disks with dimensions of 160 
µm thickness and 2 mm diameter. These disks were cultured in media at 37˚C over a period of 14 
days. Cell viability was quantitatively evaluated using MTS assays. The absorbance density 
measurements obtained from these assays on 1, 4, 7, and 14 days were converted to relative cell 
viability (%) by normalizing to 0 days. In the second study, the viability of encapsulated OVCAR-
8 cells in the microfluidic device was tested at three time points (day 4, 7 and 14) by staining them 
using the live/dead assay. 2x PBS was pumped into the channels to wash out the growing media 
from encapsulated cells. Then the live/dead staining solution was pumped for 5 min at 37ºC. To 
remove unbound reagents, cells were washed again with PBS. Nikon A1R fluorescence confocal 
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microscope was used to observe encapsulated cells. This assay identifies esterase activity in live 
cells via green fluorescence emission from calcein AM and nuclear permeability in dead cells via 
red fluorescence emission from propidium iodide.  
4.2.6 Effect of NPs Morphology and Targeting on Tumor Accumulation 
Fluorescently labeled lipid nanoparticles namely (discs, vesicles, discs w/FA, and vesicles 
w/FA) were diluted individually in phenol-free RPMI-1640 media to a final concentration of 1 
mg/mL. Then they were pumped through the chambers by the syringe pump under a constant flow 
condition for 12 hours, and images were taken using a confocal microscope. A comparison of the 
fluorescent intensity was performed to observe the effect of NPs shape or targeting on the 
accumulation in the tumor.  
4.2.7 Confocal Microscope Conditions for the Microfluidic Device 
The microfluidic device was mounted on a microscope stage inside a 37˚C incubator. Media 
containing NPs was pumped at a flow rate of 12.96 µL/min which is relevant to blood flow in 
tissue capillaries, [193, 194] and was controlled using a syringe pump. NPs accumulation images 
were taken using a 40X emersion objectives on a Nikon A1R confocal microscope. Images were 
taken in the center layer of the 3D tumor every 10 min for 12 hours.  
4.2.8 Calculating the Rate of NP Accumulation 
Fluorescence distribution was analyzed in ImageJ by drawing a contour around the cell 
aggregates freehand and measure the mean fluorescence at the various time point. Results were 
collected after 1 hour and after 12 hours. Accumulation of NPs in the tumor tissue was obtained 
by taking the mean fluorescence in selected images and normalizing to fluorescence of the 
surrounding media. The final accumulation data was obtained after subtracting the background.  
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4.3 Results and discussion 
4.3.1 Characteristic of the Microfluidic device 
The device consisted of the main chamber area, two media reservoirs as shown in (Figure 
4.2). The main chamber area, which measures about 10125 µm (length) × 2200 µm (width) × 160 
µm (height) was used for tissue culture. As highlighted in (Figure 4.2), the photo-cross-linked gel 
encapsulating cells was located between the two red lines. The PDMS posts in 100 µm radius guide 
and retain the viscous cell–gel solution during loading, thus giving the cell–gel a definable 
geometry after photocrosslinking, and serve as lateral but porous supports for the cellular gel. The 
device was also designed for direct in vitro cell observation in 3D structure under controllable 
flow. Thus, the chamber has to be optically transparent under low or high magnification. Using 
the device for in vitro observations with the media compartments at the sides improved the optical 
imaging to monitor the transportation of the NPs.   
 
Figure 4-2. A picture of the microfluidic device show the microchannel in blue. The central channel 
for cell encapsulation is between the two red lines. Two inlet tubes and two outlet tubes for media 
supplement and waste removal, respectively. 
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4.3.2 Evaluation of cell aggregation in the hydrogel 
To evaluate the growth of OVCAR-8 cells in PEG 20K hydrogel inside the microfluidic 
devices, several micro images were taken via Zeiss Axiovert 40 CFL inverted microscope at 
several time points starting at the day of encapsulation up to 14 days. Images were analyzed in 
ImageJ to measure the size of aggregates and tumor formation by measuring the diameter of each 
aggregate. The result in (Figure 4.3) indicates that OVCAR-8 cells start to form small aggregates 
after 48 hours of encapsulation and continue to grow to reach 270 µm in the largest diameter of 
the aggregate at day 7. Since the attempt to mimic the ECM of ovarian cancer is very critical, we 
chose to use PEG 20K as the matrix for cell encapsulation. This type of hydrogel was used in 
several studies for tissue engineering and stem cells proliferation,[195, 196] where the results 
suggested that the microenvironment created by PEG 20K modulate the fate of cell differentiation 
and aggregation.[197]    Therefore, we were expecting to observe the same phenomena, where 
OVCAR-8 cancer cells proliferate and aggregate in a similar microenvironment.  
Figure 4-3 Size measurements of OVCAR-8 cell aggregates in PEG 20K microfluidic over time. 
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4.3.3 Cell viability 
Studying the long-term survival of OVCAR-8 ovarian cancer cells encapsulated in the 3D 
hydrogel matrix required the use of two different approaches to examine cell viability. The MTS 
assay results in (Figure 4.4) indicated that the cell numbers were increased after 24 hours, which 
was maintained for seven days. However, a decrease in cell numbers by 36% was observed by the 
end of 14 days. Qualitative LIVE/DEAD, cell viability stain, was also performed. Representative 
images (Figure 4.5) showed an increase in the dead cells over later time points, which supported 
the results of the quantitative MTS assay.  
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Figure 4-4. OVCAR-8 cell viability over 14 days in PEG 20K hydrogels. The absorbance at (490 
nm) values quantified by MTS assays were normalized to 0 day. All values are mean ± standard 
deviation of n = 3. 
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Figure 4-5 Live and dead cells were indicated by calcein-AM (green) and propidium iodide (red), 
respectively. 
 
 
 
4.3.4 Nanoparticle penetration based on morphology and targeting effects 
The main application of our tumor on a chip in this study is to address several concerns about 
the transportation and accumulation of NPs in the tumor tissue. Since it has been difficult to 
address the delivery of NPs using either animal models or cell culture experiment, this approach 
should be very useful for real-time imaging and better understanding.  In the first set of 
experiments, we examined the effect of NP shape on their accumulation in the tumor tissue. 
Fluorescently labeled lipid-based nanodiscs and nanovesicles were administered individually to 
the OVCAR-8 3D tumor in the microfluidic chip for 12 hours at a flow rate of 12.96 µL/min. The 
penetration of NPs was quantified based on the fluorescence intensity of the NPs in the tumor 
using ImageJ, and the results are also presented in (Figure 4.6 A). Also, the accumulation of either 
nanodiscs or nanovesicles into the tumor tissue after 1 of continues flow were captured with 
confocal microscopy as shown in (Figure 4.6 B). The nanodiscs started to be visible inside the 
tumor within the first 10 min and continued to increase relatively with time. In contrast, the 
nanovesicles showed significantly less accumulation within the tumor tissue, and they started to 
appear in very low visibility after 60 min. It has been hypothesized that the accumulation of 
14 Days 7 Days 4 Days 
4 Days 7 Days 14 Days 
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filomicelles NPs in the tumor tissue is controlled by EPR effect, and due to the morphology of 
these NPs, they can move around obstacles into tumors through small leaky vasculatures.[198] If 
we based our results on that, then the highest accumulation of nanodiscs compared to nanovesicles 
is due to their morphology which allows them to penetrate through the ECM faster than that of the 
vesicular NPs.  
 
Figure 4-6 Effect of NPs shape on tumor accumulation. (A) The quantification of fluorescently 
labeled discs and vesicles penetration into the tumor tissue during the first hour, (B) micrographs 
were taken at the end of 1 hour. Scale bar is 100 µm. 
(A) 
(B) 
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Next, we used the tumor on a chip to verify the effect of PEG-folate to target folic acid 
receptors on the tumor cells. A comparison of the penetration of disc w/FA and vesicles w/FA was 
conducted on OVCAR-8 tumor aggregates in the microchannel. Diluted NPs were pumped to the 
microchannel at 12.96 µL/min, and pictures were taken every 10 min for 12 hours. Results 
indicated that the average fluorescence of targeted NPs accumulation in the tumor by the end of 
the first hour was significantly increased with respect to time (Figure 4.7). 
The results were also compared with none targeted discs and vesicles. By the end of the 
experiment, the accumulation of discs’ w/FA was improved by about 39% compared with none 
targeted discs. Moreover, the accumulation of vesicles w/FA increased by 42% compared to the 
results of vesicles because of the effect of the active targeting. However, the accumulation of the 
discoidal NPs still dominant either with or without targeting. Discs w/FA proved to have the 
maximum tumor accumulation of 79% more than that of vesicles w/FA as seen in (Figure 4.8).  
Therefore, we demonstrated from these findings that folate active-targeting NPs could increase 
accumulation compared with diffusion alone. Also, in all settings we verified the importance of 
NPs shape in the enhancement of penetration and delivery to tumor tissue. This must be useful 
before conducting any in vivo tests.  
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Figure 4-7 Effect of NPs targeting on tumor accumulation. (A) The quantification of fluorescently 
labeled discs and vesicles penetration into the tumor tissue during the first hour, (B) micrographs 
were taken at the end of 1 hour. Scale bar is 100 µm. 
 
A 
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Figure 4-8 Comparison of active and passive accumulation in tumor tissue after 12 hours. Scale 
bar is 100 µm. 
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4.4 Conclusion 
Our design of the microfluidic device shows very promising potential over previous in vitro 
studies where tumor spheroids used to stay in a static solution for several hours to be disrupted 
before or after incubation with nanocarriers.[110, 128, 190] Here the tumor intact by the 
surrounding hydrogel which mimics the microstructure of the ECM of most solid tumors.[199, 
200] also, the design reveal the real-time imaging of tumor using confocal microscopy which 
provided a way into understanding the interactions between NP and tissue under controllable flow 
conditions at very early stage. Our experimental set-up permits more accurate assessment of the 
impact of NP’s physicochemical properties (i.e. shape and targeting) on its transportation through 
the ECM and eventually into the tumor. The information we collected from our study of monitoring 
the early interaction between NP and tissue using microfluidic for 3D tumor aggregates may 
successfully predict the behavior of NPs in the long-term in vivo studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
83 
 
 
Chapter 5. Summary and Future Directions 
 
 
5.1 Summary  
Since nanotechnology gained a huge attention in the world of cancer treatment and 
diagnostic, it is essential to uncover some of the fundamental design criteria to improve the 
efficiency of nanoparticle delivery and uptake. In this work, we have accomplished several 
significant findings toward a better understanding of the nano-bio interactions. First, our work 
verified the importance of the morphology of NPs in the enhancement of delivery and cellular 
retention. As of today, most of the cancer drug carriers that are commercially used were in the 
spherical shape. However, here we could synthesize very stable discoidal lipid-based 
nanostructures and substantiated their advantageous to interact with different types of cancer cells 
over the vesicular NPs which were made from the same lipid mixture. Also, we demonstrated that 
several cancer cells (i.e. CCRF-CEM, KB and Ovcar-8 cell lines) respond differently to the 
morphology of the nanoparticle, and thus, they had different mechanisms of uptake based on each 
shape. These observations are crucial to providing a direct benefit for enhanced delivery of 
nanocarriers to cancer cells.  
This work also covered the importance of targeting molecules in enhancing delivery and 
uptake by cancer cells. Targeting with folic acid has been used because of its very high binding 
affinity, and the exceeding distribution of its receptors on the surface of many cancer cells. Our 
results exposed the impact of targeting in the improvement of cellular uptake of both discoidal and 
vesicular lipid-based nanoparticles. In addition, it confirmed our previous findings that shape is 
matter and discoidal folate lipid NPs have more potential in cancer treatment and diagnostic. We 
also proved that folate NPs were mainly internalized into cancer cells via folate receptor-mediated 
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endocytosis.  Also, we demonstrated that folate NPs were localized in cytoplasm indicating that 
they followed endocytosis pathway to internalize into the cells. Then they were distributed in the 
cytoplasm after escaping from the endosome and the lysosome. During the animal study, we 
observed a higher tumor uptake of folate disc NPs in comparison with folate vesicle NPs at 
different time points. Similar observation was made in the case of none folate disc NPs and none 
folate vesicle NPs. These results are strong evidence of the role of both morphology and targeting 
in the enhancement of the penetration of NPs in the tumor.  
Moreover, this makes our findings especially significant because it provides a detailed 
quantitative analysis of the interplay between shape and cellular uptake, which offers principles 
for drug carrier design. The significant of the discoidal shape of the self-assembled lipid 
nanoparticle over the vesicular one offers potential application of this nanostructure in cancer 
diagnostic and therapeutic.   
To extend our understanding of the relationship between the design of the nanoparticles and 
their interaction with the tumor and the surrounding tissue structure, we developed the concept of 
tumor on the chip to serve as a backbone for future in vivo tests. The design, fabrication, and 
evaluation of hydrogel cell culture microfluidic device that can be used to monitor nanoparticle 
penetration and delivery to 3D cancer cells was accomplished in this study, too. The device met 
all essential design criteria for this application, including the viable cell culture in a 3D matrix, the 
imposition of fluid flow through the 3D cell culture, and the live cell imaging during perfusion. 
Moreover, we could proof the feasibility of using this device to investigate the effect of shape 
(discoidal and vesicular) with the addition of folic acid (FA) targeting on the penetration of 
nanoparticle through the hydrogel to 3D ovarian cancer cells. That may lead to identifying the 
dosage of anticancer drugs for in vitro experiments, saving time and reducing costs.  
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The above contributions will advance the field of nanoparticles manufacturing for drug 
delivery and will improve the efficacy of cancer treatment. It should be noticed that the simplicity 
of the fabrication process of our nanocarriers, as well as the uniformity and the stability of the 
obtained structure, can be used for the next generation of drug carriers. Overall, this study of 
several in vitro tumor models has highlighted the unique potential and flexibility of the shape and 
targeting specific nanoparticles in versatile implications in the field of tumor therapeutics and 
diagnostics.  
5.2 Future studies    
As of future work, the encapsulation of hydrophobic anticancer drugs in the bilayers of the 
discoidal lipid nanoparticles is our next step. Thus, we could verify the effectiveness of the 
discoidal lipid nanoparticles in drug delivery.  Also, we may incorporate imaging agents such as 
quantum dots with the drug to serve both as a diagnostic and therapeutic carrier. Furthermore, the 
microchannel device we fabricated here can be used as a platform to investigate the compatibility 
of the nanocarriers. Several types of cells can be encapsulated in the microfluidic device including 
cancer, normal and stem cells to investigate in real time the trafficking and fate of the nanoparticles 
with each cell type. Further analysis of the transportation of the nanoparticle inside the blood 
vessels and all the way to the target tissue will be performed. Conducting mathematical analysis 
could be useful to improve the design of the microchannel device.  Moreover, confirming these 
results must be performed in vivo before applications in drug delivery can be considered further.  
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